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1. Introduction 
The problem of antibiotic resistance among pathogenic bacteria 
is as old as antibiotics itself.1 Due to the emergence of multidrug 
resistant pathogens, there is a continuous quest for new cellular 
targets which are vital for survival of the pathogen or for new 
antimicrobial agents interfering with known targets.2 In recent 
years, aminoacyl-tRNA synthetases (aaRSs) have emerged as 
attractive and clinically validated targets for antimicrobial drug 
development as exemplified by the clinical use of mupirocin 
[isoleucine-tRNA synthetase (IleRS) inhibitor].3 More recently 
different borate containing small molecules have progressed into 
clinical trials, and are targeting the editing site of aaRSs, further 
underpinning the idea of aaRSs being an excellent target for 
antibiotic development.4-8 These enzymes are at the heart of 
translation and responsible for ligation of the correct amino acid to 
their cognate tRNA.5, 9 Aminoacylation of tRNA occurs in a two-
step process. The first step involves formation of aminoacyl-
adenylate (aa-AMP) followed by transfer of the aminoacyl moiety 
to the 3’-terminal adenosine of the respective tRNA. These 
aminoacyl-tRNAs are further used in translation and are pivotal in 
determining fidelity of protein synthesis. Because of their crucial 
role in protein synthesis, inhibition of these enzymes proves 
detrimental to the cell.10 Although, aaRSs are essential in all living 
organisms, selective inhibition of bacterial aaRS over their human 
——— 
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orthologs is a big hurdle for discovering novel aaRS inhibitors as 
potential antibiotics. 
[insert Figure 1 here] 
 
The early efforts in the search for aaRS inhibitors yielded 
diverse sets of chemical structures which are either a substrate 
mimic or mimic of the reaction intermediate (aa-AMP). The 
largest group of aaRS inhibitors are analogues of the aa-AMP in 
which the labile acyl-phosphate linkage is replaced with relatively 
stable aminoacyl-sulfamates,11-15 aminoalkyl phosphates,11, 12, 16 
esters,17-19 amides,17 hydroxamates,17-19 sulfamides,11, 12 N-
alkoxysulfamides or N-hydroxysulfamides.20 Among them, 
aminoacyl-sulfamate derivatives yielded the more potent 
inhibitors. Isoleucyl sulfamoyl adenosine (IleSA, 1a, Figure 1) is 
given as an example for this class of inhibitors. Unfortunately, 
these analogues lack selectivity for bacterial aaRSs as compared 
to their human aaRSs due to structural similarity with aa-AMP. In 
addition, the lack of cell penetration further limits their clinical 
use.  
Several modifications have been attempted in order to improve 
the selectivity of these aminoacyl sulfamoyl adenosine analogues. 
In 1998, Cubist Pharmaceuticals reported the synthesis and 
evaluation of a new class of aaRS inhibitors where the adenine 
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base is replaced with an aryl-tetrazole moiety and linked to the 
sugar part through a two carbon chain. The most important 
compounds of this series (2 and 3) are likewise depicted in figure 
1. These compounds exhibit excellent potency (IC50 values in the 
nanomolar range) with improved selectivity (up to 3000-fold) over 
human IleRS. However, further development was halted due to 
their lack of in vivo activity and high serum albumin binding.3, 21  
Further replacement of ribofuranose of 1a with 2’- or 3’-deoxy or 
2’,3’-dideoxy sugars (1b,c,d Figure 1) yielded less potent aaRS 
inhibitors. The 2’-deoxy, 3’-deoxy and 2’, 3’-dideoxy analogues 
displayed 1300-fold, 2600-fold and 4-fold reduction in enzyme 
inhibition respectively as compared to IleSA (1a).22  
[insert Figure 2 here] 
An example of the use of a modified base to substitute for 
adenine can be found in nature as well, wherein albomycin is 
produced by Streptomyces species as a mixture of the closely 
related substances (4a-c, Figure 2) being a natural Trojan-Horse 
antibiotic.23 Especially albomycin 2 (4b) is highly effective 
against many gram-negative and some gram-positive pathogens 
(with a MIC of 10 ng/mL against Streptococcus pneumonia).24 
Albomycin is a so called siderophore-drug conjugate (SDC) and 
consists of the antibiotic moiety linked to an iron carrier part 
(ornithine-based trihydroxamate) called the siderophore and 
promoting its uptake. A modified pyrimidine is attached at the 1’-
position of a thioribofuranosyl moiety. Once internalized via an 
ATP dependent iron channel, the ferric ion is reduced to ferrous 
cation by ferric reductase and the siderophore part is metabolized 
by non-specific peptidases. This in turn releases the active moiety 
which resembles seryl-adenosine monophosphate (SerAMP) and 
inhibits seryl-tRNA synthetase (SerRS), but shows considerable 
deviation of the standard adenine base moiety.25  
Microcin C (McC) (5a, Figure 2) on the other hand is a natural 
antibiotic produced by Escherichia coli and consists of a 
formylated heptapeptide of which the terminal aspartic acid is 
attached to a modified AMP via a phosphoramidate linkage to its 
-carboxylic acid moiety.26, 27 As of its peptidic signature, it is 
actively taken up by E. coli through the YejABEF transporter.26 
Once internalized, it is processed by a peptide deformylase and 
one of the three aminopeptidases, pepA, pepB or pepN to release 
a non-hydrolyzable analogue of aspartyl adenylated (5b, Figure 2) 
which selectively inhibits aspartyl-tRNA synthetase (AspRS).28 In 
view of their prodrug like properties, both albomycin and McC 
therefore are called Trojan-Horse antibiotics. 
The high selectivity of aryl-tetrazole containing sulfamates3, 21 
and the excellent efficacy of albomycin against Streptococcus 
pneumonia24 both deviating from the adenine base structure while 
yet acting as aaAMP analogues, prompted us to investigate the 
pharmacophoric importance of the adenine base for the well-
known aminoacyl sulfamoyl adenosine (aa-SA) inhibitors. We 
therefore intended to evaluate a series of aaSA analogues with 
different natural or unnatural heterocyclic bases substituting for 
the adenine ring. To our knowledge, such substitution of the 
adenine base has not been attempted so far. Towards this end, we 
designed, synthesized, and evaluated several isoleucyl-sulfamoyl 
nucleoside analogues with either uracil (U), cytosine (C), 
hypoxantine (I), guanine (G), 1,3-dideaza-adenine [4-amino-
benzimidazole (4-ABI)] or 4-nitro-benzimidazole (4-NBI) as the 
heterocyclic base. We further compared their antibacterial activity 
with the parent Ile-SA, both in vitro and in cellular assays. 
2. Chemistry 
The corresponding series of isoleucyl sulfamate analogues were 
prepared combining different literature procedures. The required 
nitrobenzimidazole heterocycle was synthesized starting from o-
phenylene diamine via its selenium complex29 followed by 
nitration,30 reduction,31 and cyclization32 using triethyl 
orthoformate yielding 4(7)-nitrobenzimidazole (Scheme 1).  
[insert Scheme 1 here] 
The heterocyclic base was further reacted with tetra-O-acetyl 
ribofuranose using stannic chloride32 followed by deprotection of 
the acetyl moieties using methanolic ammonia yielding the 4-nitro 
benzimidazole nucleoside analogue 12a. All sulfamoylated 
nucleoside analogues (natural and unnatural ones) were further 
synthesized following literature procedures which involved 
persilylation of the nucleoside followed by selective removal of 
the 5’-TBDMS protection and reaction of the liberated 5’-
hydroxyl group with in situ formed sulfamoyl chloride.33 Finally, 
the isoleucyl sulfamate analogues were obtained by condensation 
of the active ester of Boc-Ile (in form of Boc-Ile-OSu) with the 
respective sulfamoylated analogues (15a-f) using DBU as a base 
in DMF. The Boc group was deprotected by acidolysis using 
TFA/water and TBDMS groups were cleaved by Et3N.3HF 
affording the desired isoleucyl sulfamate analogues (16a-f). 
Finally, the 4-nitro moiety in 16a was reduced by hydrogenation 
using Pd/C under H2 atmosphere to yield 16g (Scheme 2). The 
hexapeptide uptake signal was further coupled to the analogues 
16a-g to afford derivatives 17a-g following a previous protocol34 
(Scheme 3). 
[insert Schemes 2 and 3 here] 
3. Biological evaluation 
The obtained analogues were evaluated for inhibition of 
isoleucine incorporation in tRNA under in vitro aminoacylation 
conditions. Hereto, tRNAIle aminoacylation reactions were carried 
out in E. coli cell extracts in presence of the respective test 
compounds, and using radioactively labeled isoleucine as 
described before (Figure 3).27 The remarkable order of inhibitory 
activity found for the different sulfamates surprisingly showed the 
strongest inhibition for the U analogue 16f followed by I > 
adenine= C > 4-ABI > 4-NBI > G. Excited with the results from 
our in vitro aminoacylation experiments, we evaluated the 
analogues 16a-g for their ability to inhibit the growth of 
microorganisms by a disc diffusion method (data not shown). In 
line with previous results34 none of the analogues showed growth 
inhibitory activity (maximum concentration tested was 5 mM). 
 
 
 
 
 
 
 
 
Hexapeptidyl (formyl-MRTGNA-OH) conjugates of these 
analogues likewise were evaluated for their growth inhibitory 
properties. Unfortunately, none of conjugates 17a-g displayed any 
activity against E. coli wt (Figure 5). Upon evaluation with the E. 
coli Ara-Yej inducer strain (BW39758)34 transient inhibition could 
be seen after 8 h incubation for the adenosine conjugate 17b and 
to a lower extent for the purines 17d and 17g. The uracil conjugate 
17f however was devoid of inhibitory activity (Figure 6). 
4. Discussion 
Several non-hydrolysable analogues of aa-AMP have been 
reported in literature as inhibitors of aaRS with the aaSAs 
displaying nanomolar affinity for the corresponding aaRS in vitro. 
These inhibitors however lack selectivity for bacterial aaRSs as 
compared to their human orthologs due to structural similarity with 
aa-AMP. Visual inspection of the compounds reported by Cubist 
Pharmaceuticals, and of albomycin and mupirocin reveals that 
these structures vary from aaSA analogues in having a heterocyclic 
base or a modified base or no base moiety at all as in mupirocin 
respectively. These observations prompted us to re-investigate the 
pharmacophoric importance of the adenine base in aaSAs. IleRS, 
being extensively studied as aaRS target before (e.g. the mupirocin 
studies and the Cubist Pharmaceuticals inhibitor program), was 
chosen to study the effect of different bases substituting for 
adenine. Hereto, isoleucyl-sulfamoyl nucleoside analogues 
comprising either a natural base like G, I, U or C, or the unnatural 
base 4-NBI or 4-ABI (the latter corresponding to 1,3-dideaza 
adenine) were envisaged. The natural nucleobase containing 
analogues were prepared to investigate the effect of pyrimidine 
versus purine analogues, whereas the sulfamates containing an 
unnatural base aimed at evaluating the importance of N1 and N3 of 
the adenine ring, respectively. All analogues were synthesized as 
outlined in Scheme 2.  
From the in vitro aminoacylation experiments it can be 
concluded that these molecules act as IleRS inhibitors (Figure 3). 
The remarkable order of inhibitory activity found for the different 
sulfamates showed the strongest inhibition for the U analogue 
(16f) followed by I > adenine= C > 4-ABI > 4-NBI > G. This 
implies that the adenine base or a purine ring per se is not a 
prerequisite for aaRS inhibition. Furthermore, U and C analogues 
proved to be either more or equally active respectively, as 
compared to the adenine base. The latter is rather unexpected in 
view of their small size occupying only part of the active site. 
While I is well tolerated, addition of the C-2 amino moiety as in 
the G analogue resulted in a significant decrease in activity 
possibly due to steric clashes. The unnatural 1,3-dideaza-adenine 
containing analogues displayed lower activity, most probably in 
view of loss of the reported H-bonding of the adenine N3 position 
with a His residue of the active site.35 The 4-NBI analogue (16a) 
proved less active compared to its reduced counterpart, the 4-ABI 
(1,3-dideaza adenine) analogue suggesting the possible interaction 
of the amine with the synthetase active site. In contrast, in the 
reported IleRS.IleAMS of Nakama et al. (with IleAMS being a 
close analogue to IleSA with nitrogen substituting for the 5’-
oxygen), the adenine N6 atom is too far to allow hydrogen 
bonding.35 
[insert Figure 3 here] 
The strong in vitro inhibition shown by both pyrimidine 
containing compounds is rather unexpected in view of the 
omnipresent and more spacious adenosine being used in the 
majority of biochemical processes. We therefore tried to get some 
insight into the binding pocket of IleRS, and made an attempt to 
carry out some molecular simulations with the synthesized 
inhibitors using a homology modeled IleRS. The E. coli IleRS 
structure being not available in the protein databank, a homology 
model was created using the I-tasser server36 starting from the E. 
coli MetRS structure (1PG0); (see methods). The newly developed 
inhibitors were then superimposed onto the original inhibitor 
present in 1PG0 (see Figure 4).  
[insert Figure 4 here] 
In using a homology model for our analysis, we cannot use a 
classical program to dock the inhibitors into the binding site of 
tRNA synthetase. Numerous amino acid side chains, in addition to 
the many flexible dihedrals from the inhibitors, would have to be 
adjusted to accommodate the inhibitors. Unfortunately, the noise 
on the calculation of the interaction energy values for the different 
inhibitors proved too large to allow for a clear classification. 
[insert Figure 5 here] 
Despite the exciting results from the in vitro aminoacylation 
experiments, no growth inhibitory activity on microorganisms was 
found for the analogues 16a-g by a disc diffusion method up to 
maximum concentration tested of 5 mM. This lack of activity 
corresponds with the general lack of activity in a whole-cell assay 
as shown before34 and can be related to limited cell-penetration in 
accordance with the lack of in vivo efficacy for the IleSA analogue 
16b. Hence with the microcin C strategy in mind, hexapeptidyl 
conjugates of these analogues were prepared in an effort to 
improve the uptake of these compounds via a Trojan-horse 
mechanism. Hence, the conjugates 17a-g were evaluated against 
E. coli wt (Figure 5) or E. coli Ara-Yej inducer (BW39758) strain 
(Figure 6) in a broth dilution test. The latter strain upon arabinose 
induction shows an increased expression of the transporter.34 
Unfortunately, only some transient antibacterial activity was 
noticed for purine derivatives 17b, 17d and 17g following 
incubation with the inducer strain, while no antibacterial activity 
could be recorded for the in vitro strongly active uracil derivative 
17f. As it has been shown previously that the hexapeptide is 
effectively metabolized by non-specific peptidases37 failure of 
uptake is the likely reason for the low activity of these 
hexapeptidyl conjugates. Hence, being the only different part of 
these constructs, the heterocyclic base might play an important 
role for recognition by the transporter as was seen with the 
tetrazole analogues when coupled to the peptidic carrier.37 
[insert Figure 6 here] 
 
 
 
 
 
 
 
 
5. Conclusion 
A series of isoleucyl-sulfamoylated nucleoside analogues 
comprising different base substitutions was synthesized in an 
effort to evaluate the pharmacophoric importance of the adenine 
ring for recognition by IleRS. Upon in vitro evaluation in a cellular 
extract, surprisingly the uracil containing analogue 16f was shown 
to be endowed with the highest inhibitory properties. To promote 
their bacterial uptake, these polar sulfamoylated analogues were 
converted into their respective hexapeptidyl conjugates in analogy 
with the natural Trojan-horse antibiotic microcin C. 
Unfortunately, only weak inhibitory properties could be noticed 
for the adenosine analogue 17b and not for the conjugate 17f 
comprising the uracil moiety. 
6. Experimental section 
6.1. Materials and Methods 
Reagents and solvents were purchased from commercial 
suppliers (Acros, Sigma-Aldrich, Bachem, Novabiochem) and 
used as provided, unless indicated otherwise. DMF and THF were 
of analytical grade and were stored over 4Å molecular sieves. For 
reactions involving Fmoc-protected amino acids and peptides, 
DMF for peptide synthesis (low amine content) was used. All other 
solvents used for reactions were analytical grade and used as 
provided. Reactions were carried out in oven-dried glassware 
under a nitrogen atmosphere with stirring at room temperature, 
unless indicated otherwise. 1H and 13C NMR spectra of the 
compounds dissolved in CDCl3, CD3OD, DMSO-d6 or D2O were 
recorded on a Bruker UltraShield Avance 300 MHz or 500 MHz 
spectrometer. The chemical shifts are expressed as δ values in 
parts per million (ppm), using the residual solvent peaks (CDCl3: 
1H 7.26 ppm; 13C, 77.16 ppm; DMSO: 1H, 2.50 ppm; 13C, 39.52 
ppm; HOD: 1H, 4.79 ppm or 4.975 at 5 oC; CD3OD: 1H, 3.31 ppm; 
13C, 49.00 ppm) as a reference. Coupling constants are given in 
Hertz (Hz). The peak patterns are indicated by the following 
abbreviations: bs = broad singlet, d = doublet, m = multiplet, q = 
quadruplet, s = singlet and t = triplet. Signal assignment for 1H and 
13C in the conjugate compounds 17a-g were obtained using 
[1H,1H]-DQF-COSY,38 [1H,13C]-HSQC39 and [1H,13C]-HMBC40 
spectra were recorderd on Bruker Avance II 600 with a TCI 
gradient cryoprobe. High resolution mass spectra were recorded 
on a quadrupole time-of-flight mass spectrometer (Q-Tof-2, 
Micromass, Manchester, UK) equipped with a standard ESI 
interface; samples were infused in 2-propanol/H2O (1:1) at 3 
µL.min-1.  
For TLC, precoated aluminium sheets were used (Merck, Silica 
gel 60 F254). The spots were visualized by UV light at 254 nm. 
Column chromatography was performed on ICN silica gel 60A 
60–200 m. Final products were purified using a PLRP-S 100Ǻ 
column connected to a Merck-Hitachi L6200A Intelligent pump. 
Eluent compositions are expressed as v/v. Purity was checked by 
analytical HPLC on a Inertsil ODS-3 (C-18) (4.6 x 100 mm) 
column, connected to a Shimadzu LC-20AT pump using a 
Shimadzu SPD-20A UV-detector. Recordings were performed at 
254 nm and 214 nm. 
6.1.1 .  2,1,3-benzose lenadiazole  (7 ) 2 9  
An amount of 6 (10.5 g, 97.1 mmol) and selenium dioxide 
(11.85 g, 106.8 mmol) were refluxed in absolute ethanol (100 mL) 
for 10 min. The reaction mixture was cooled to rt and ethanol was 
evaporated in vacuo. The product was precipitated from water to 
yield 17.6 g (96.1 mmol, 99% yield) of 7 as a faint pink coloured 
solid: 1H NMR (300 MHz, CD3OD)  7.46-7.52 (m, 2H, Ar), 7.76-
7.83 (m, 2H, Ar). 13C NMR (75 MHz, CD3OD)  124.2, 130.6, 
161.6 (C=N). HRMS for C6H5N2Se ([M+H]+) calcd: 184.9612 
found 184.9616. 
6.1.2 .  4-ni t ro-2,1 ,3-benzose lenadiazole  (8 ) 3 0  
A mixture of 9.1 mL of conc. nitric acid and 18.2 mL of conc. 
sulphuric acid was added to a solution of 7 (16.7 g, 91.2 mmol) in 
conc. sulphuric acid (36.5 mL) at 0 oC. The solution was allowed 
to stir at room temperature for 30 min and then poured into excess 
ice water. The precipitate was filtered off and washed with distilled 
water to yield 20.8 g (91.2 mmol, quantitative) of the title 
compound 8 as yellow solid: 1H NMR (300 MHz, DMSO-d6)  
7.72-7.78 (dd, 1H, J = 7.5 Hz and 8.7 Hz, H-meta to nitro), 8.29 
(d, 1H, J = 8.7 Hz, H-para to nitro), 8.46 (d, 1H, J = 7.5 Hz, H-
ortho to nitro). 13C NMR (75 MHz, DMSO-d6)  126.4, 126.8, 
129.4, 140.5, 149.9, 159.9. HRMS for C6H4N3O2Se ([M+H]+) 
calcd: 229.9463 found 229.9668. 
6.1.3 .  3-ni t ro-1,2-phenylenediamine  (9 ) 3 2  
To a suspension of 8 (18 g, 79 mmol) in conc. hydrochloric acid 
(225 mL), 70 mL of aqueous hydroiodic acid (57% w/v, 70 mL) 
was added dropwise at room temperature with vigorous stirring. 
The reaction mixture was stirred further at room temperature for 3 
h. A 5% aqueous sodium hydrogen sulphide solution (400 mL) 
was added to the dark-red reaction mixture. This was then warmed 
to 80 oC and filtered hot and afterwards cooled to 4 oC. The needle 
like salt of the diamine crystallized out. The product was 
neutralized with 30% NaOH to pH 8 and extracted with ethyl 
acetate (6x100 mL). The ethyl acetate layer was collected, dried 
over Na2SO4, filtered off and evaporated to yield 6.5 g (42.44 
mmol, 54%) of the title compound 9 as a red solid: 1H NMR (300 
MHz, CD3OD)  6.47-6.56 (dd, 1H, J = 7.5 Hz and 8.7 Hz, Ar), 
6.87-6.92 (dd, 1H, J = 1.2 Hz and 7.5 Hz, Ar), 7.48-7.53 (dd, 1H, 
J = 1.2 Hz and 8.7 Hz, Ar).13C NMR (75 MHz, CD3OD)  116.4, 
117.0, 120.6 (quaternary carbon not detected). HRMS for 
C6H7N3O2Na ([M+Na]+) calcd: 176.0431 found 176.1058. 
6.1.4 .  4(7)-n i t ro-benz imidazole  (10 ) 3 2  
A mixture of 9 (6 g, 39.2 mmol) and triethyl orthoformate (150 
mL) was refluxed at 145 oC for 4 h. The solution was evaporated 
to dryness with a rotary evaporator and the residue obtained was 
dissolved in formic acid (150 mL) and refluxed for 3 h at 110 oC. 
When the reaction was completed, the excess formic acid was 
removed in vacuo and the residue was dissolved in methanol (150 
mL) and treated with activated charcoal by overnight stirring at 
room temperature. The charcoal was removed by filtration through 
celite and the filtrate was evaporated to dryness. The residue 
obtained was subjected to silica gel column chromatography to 
afford 5.54 g (34 mmol, 87 %) of 10 as a yellow solid: 1H NMR 
(300 MHz, DMSO-d6)  7.43 (t, 1H, J = 8.1 Hz, H-5/6), 8.16 (d, 
 
 
 
 
 
 
 
 
2H, J = 8.1 Hz, H-4/7 and H-6/5), 8.45 (s, 1H, H-2), 8.47 (bs, 1H, 
NH). 13C NMR (75 MHz, DMSO-d6)  118.9 (C-5/6), 121.2 (C-
4/7), 126.6 (C-6/5), 145.3 (C-2). HRMS for C7H4N3O2 ([M-H]-) 
calcd: 162.0309 found 162.0314. 
6.1.5 .  1-(2’ ,3’ ,5’- tr i -O-acety l - -D-r ibofuranosyl ) -
4-ni t robenz imidazole  (11 ) 3 2  
The compound 10 (1.2 g, 7.36 mmol) and 1’,2’,3’,5’-tetra-O-
acetyl--D-ribofuranose  (2.81 g, 8.83 mmol) were dissolved in 30 
mL of dry acetonitrile. A solution of stannic chloride (1M in DCM, 
22.1 mL, 22.1 mmol) was added and the reaction mixture was 
stirred at 25 oC for 16 h. The reaction mixture was diluted with 
DCM and then poured under stirring into 30 mL of ice cooled 
saturated sodium bicarbonate. The resulting suspension was 
filtered through celite and the layers were separated. The organic 
layer was further washed with brine and was dried over Na2SO4, 
filtered off and evaporated. The residue was purified by silica gel 
column chromatography to yield 2.5 g (5.93 mmol, 80%) of the 
title compound 11 as pale yellow solid: 1H NMR (500 MHz, 
CDCl3)  2.10 (s, 3H, COCH3), 2.16 (s, 3H, COCH3), 2.18 (s, 3H, 
COCH3), 4.39-4.44 (m, 1H, H-5’a), 4.45-4.50 (m, 1H, H-5’b), 
4.51-4.55 (m, 1H, H-4’), 5.51 (t, 1H, J = 5.0 Hz, H-3’), 5.56 (t, 1H, 
5.5 Hz, H-2’), 6.15 (d, 1H, J = 5.5 Hz, H-1’), 7.44 (t, 1H, J = 8.0 
Hz, H-6), 7.97 (d, 1H, J = 8.0 Hz, H-7), 8.19 (d, 1H, J = 8.0 Hz, 
H-5), 8.40 (s, 1H, H-2). 13C NMR (125 MHz, CDCl3)  19.5 
(COCH3), 19.6 (COCH3), 19.9 (COCH3), 61.7 (C-5’), 69.1 (C-3’), 
72.5 (C-2’), 79.7 (C-4’), 86.5 (C-1’), 116.3 (C-5), 119.2 (C-7), 
122.1 (C-6), 134.2 (C-9), 136.9 (C-4), 138.8 (C-8), 142.8 (C-2), 
168.5 (COCH3), 168.7(COCH3), 169.1 (COCH3). HRMS for 
C18H19N3O9Na ([M+Na]+) calcd: 444.1014 found 444.1012. 
6.1.6 .  1- -D-(4-ni tro-benz imidazol -1-y l ) -
r ibofuranoside  (12a )  
The acylated precursor 11 (2.5 g, 5.93 mmol) was dissolved in 
methanolic ammonia (7N, 25 mL) at 0 oC. The reaction mixture 
was allowed to warm to room temperature and stirred overnight. 
Then the mixture was evaporated to dryness and the residue was 
partitioned between water and ether. The aqueous layer was 
evaporated to yield 1.4 g (4.74 mmol, 90%) of the title compound 
as a pale yellow solid which was used further without purification: 
1H NMR (500 MHz, DMSO-d6)  3.62-3.66 (m, 1H, H-5’a), 3.67-
3.72 (m, 1H, H-5’b), 4.03 (q, 1H, J = 3.0 Hz, H-4’), 4.14 (q, 1H, J 
= 5.0 Hz, H-3’), 4.38 (q, 1H, J = 6.0 Hz, H-2’), 5.19 (t, 1H, J = 5.5 
Hz, 5’-OH), 5.27 (d, 1H, J = 4.5 Hz, 3’-OH), 5.56 (d, 1H, J = 6.0 
Hz, H-1’), 7.48 (t, 1H, J = 8.0 Hz, H-6), 8.08 (d, 1H, J = 8.0 Hz, 
H-7), 8.27 (d, 1H, J = 8.0 Hz, H-5), 8.77 (s, 1H, H-2). 13C NMR 
(125 MHz, DMSO-d6)  61.1 (C-5’), 70.1 (C-3’), 74.1 (C-2’), 86.0 
(C-4’), 89.1 (C-1’), 118.7 (C-7), 118.8 (C-5), 122.3 (C-6), 135.5 
(C-9), 136.9 (C-8), 138.8 (C-4), 145.8 (C-2). HRMS for 
C12H14N3O6 ([M+H]+) calcd: 296.0877 found 296.0880. 
6.1.7 .  General  procedure  for  synthes is  o f  2’ ,3’ ,5’ -
t r i -O-TBDMS nucleos ides  (13a-f ) 4 1 ,  4 2  
To a stirred solution of the nucleoside (1 mmol) and imidazole 
(8 mmol) in DMF (5 mL) was added TBDMSCl (4 mmol). The 
reaction mixture was stirred at 50 oC for 3 days. After completion 
of reaction, DMF was evaporated and the residue was partitioned 
between ethyl acetate (50 mL) and saturated NaHCO3 (50 mL). 
The layers were separated and the aqueous layer was extracted 
with ethyl acetate (50 mLx3). The combined organic layers were 
washed with brine, dried over sodium sulfate, filtered and 
evaporated to yield an oily residue which was purified by silica gel 
chromatography yield persilyated derivatives in 92-98% yield. 
6.1.7 .1 .  1- -D-(4-ni tro-benz imidazol -1-y l ) -
2’ ,3’ ,5’ - t r i -O-TBDMS-r ibofuranoside  (13a )  
1H NMR (500 MHz, CDCl3)  -0.68 (s, 3H, CH3-Si), -0.16 (s, 
3H, CH3-Si), 0.12 (s, 3H, CH3-Si), 0.13 (s, 3H, CH3-Si), 0.17 (s, 
3H, CH3-Si), 0.19 (s, 3H, CH3-Si), 0.71 (s, 9H, tBu CH3), 0.96 (s, 
9H, tBu CH3), 0.98 (s, 9H, tBu CH3), 3.84-3.87 (dd, 1H, J = 2.0 Hz 
and 11.5 Hz, H-5’a), 3.95-3.99 (dd, 1H, J = 2.0 Hz and 11.5 Hz, 
H-5’b), 4.16-4.18 (m, 1H, H-4’), 4.23 (d, 1H, J = 4.5 Hz, H-3’), 
4.40-4.44 (dd, 1H, J = 4.5 Hz and 7.5 Hz, H-2’), 5.93 (d, 1H, J = 
8.0 Hz, H-1’), 7.35 (t, 1H, J = 8.0 Hz, H-6), 8.13 (d, 1H, J = 8.0 
Hz, H-7), 8.18 (d, 1H, J = 8.0 Hz, H-5), 8.34 (s, 1H, H-2). 13C 
NMR (125 MHz, CDCl3)  -6.7 (CH3-Si), -6.3 (CH3-Si), -6.2 
(CH3-Si), -5.5 (CH3-Si), -5.4 (CH3-Si), -5.3 (CH3-Si), 16.9 (tBu 
C(CH3)3), 17.2 (tBu C(CH3)3), 17.7 (tBu C(CH3)3),  24.8 (tBu, 
CH3), 25.0 (tBu, CH3), 25.21 (tBu, CH3), 62.6 (C-5’), 72.0 (C-3’), 
74.9 (C-2’), 86.7 (C-4’), 88.3 (C-1’), 117.8 (C-7), 118.9 (C-5), 
121.3 (C-6), 134.7 (C-9), 136.9 (C-8), 138.5 (C-4), 144.2 (C-2). 
HRMS for C30H56N3O6Si3 ([M+H]+) calcd: 638.3471 found 
638.3482. 
6.1.7 .2 .  2’ ,3’ ,5’ - t r i -O-TBDMS-guanosine (13c ) 4 3  
1H NMR (300 MHz, DMSO-d6)  -0.28 (s, 3H, CH3-Si), -0.08 
(s, 3H, CH3-Si), 0.09-0.12 (ms, 12H, 4xCH3-Si), 0.73 (s, 9H, tBu 
CH3), 0.9 (2s, 18H, tBu CH3), 3.68-3.73 (dd, 1H,  J = 3.9 Hz, and 
11.4 Hz, H-5’a), 3.82-3.88 (dd, 1H,  J = 5.4 Hz, 11.4 Hz, H-5’b), 
3.93-3.95 (m, 1H, H-4’), 4.17 (d, 1H, J = 4.2 Hz,  H-3’), 4.56-4.61 
(dd, 1H, J = 4.5 Hz and 6.9 Hz, H-2’), 5.74 (d, 1H, J = 7.2 Hz, H-
1’), 6.45 (bs, 2H, NH2), 7.89 (s, 1H, H-8), 10.61 (bs, NH). 13C 
NMR (75 MHz, DMSO-d6) -5.39 (3xCH3-Si), -4.67 (CH3-Si), -
4.64 (CH3-Si), -4.55 (CH3-Si), 17.7 (tBu C(CH3)3), 17.9 (tBu 
C(CH3)3), 18.2 (tBu C(CH3)3), 25.6 (tBu CH3), 25.9 (tBu CH3), 26.0 
(tBu CH3), 63.1 (C-5’), 72.9 (C-3’), 75.4 (C-2’), 85.4 (C-4’), 85.8 
(C-1’), 116.7 (C-5), 135.0 (C-8), 151.8 (C-4), 153.9 (C-2), 156.8 
(C-6). HRMS calcd for C28H56N5O5Si3 ([M+H]+) calcd: 626.3584 
found: 626.3582. 
6.1.7 .3 .  2’ ,3’ ,5’ - tr i -O-TBDMS-inosine  (13d ) 4 4  
1H NMR (300 MHz, DMSO-d6)  -0.53 (s, 3H, CH3-Si), -0.13 
(s, 3H, CH3-Si), -0.02 (s, 3H, CH3-Si), 0.01 (2s, 6H, 2xCH3-Si), 
0.74 (s, 9H, tBu, CH3), 0.94 (s, 9H, tBu, CH3), 3.71 (d, 1H, J = 12.6 
Hz, H-5’), 3.94 (d, 1H, J = 12.9 Hz, H-5’), 4.15 (bs, 1H, H-4’), 
4.37 (d, 1H, J = 4.2 Hz, H-3’), 4.82-4.92 (m, 1H, H-2’), 3.78 (d, 
1H, J = 7.5 Hz, H-1’), 7.90 (s, 1H, H-8), 8.43 (s, 1H, H-2). 13C 
NMR (75 MHz, DMSO-d6)  -5.7 (CH3-Si), -4.52 (CH3-Si), -4.47 
(CH3-Si), -4.4 (CH3-Si), 17.9 (tBu C(CH3)3), 18.2 (tBu C(CH3)3), 
25.8 (tBu CH3), 25.9 (tBu CH3), 62.9 (C-5’), 73.9 (C-3’), 74.8 (C-
2’), 89.2 (C-4’), 91.0 (C-1’), 126.7 (C-5), 140.9 (C-8), 146.3 (C-
2), 147.9 (C-4), 159.6 (C-6). HRMS for C28H55N4O5Si3 ([M+H]+) 
calcd: 611.3475 found 611.3472. 
 
 
 
 
 
 
 
 
6.1.7 .4 .  2’ ,3’ ,5’ - tr i -O-TBDMS-cyt id ine  (13e )4 2  
1H NMR (300 MHz, DMSO-d6)  -0.01 (s, 6H, 2xCH3-Si), 0.06 
(s, 3H, CH3-Si), 0.07 (s, 3H, CH3-Si), 0.09 (s, 3H, CH3-Si), 0.10 
(s, 3H, CH3-Si), 0.83 (s, 9H, tBu CH3), 0.88 (s, 9H, tBu CH3), 0.91 
(s, 9H, tBu CH3), 3.67-3.75 (m, 1H, H-5’a), 3.85-3.95 (m, 2H, H-
5’b, H-4’), 4.04 (t, 1H, J = 4.2 Hz, H-3’), 4.10 (t, 1H, J = 4.5 Hz, 
H-2’), 5.71 (d, 1H, J = 7.5 Hz, H-5), 5.82 (d, 1H, J = 4.5 Hz, H-
1’), 7.17 (bs, 2H, NH2), 7.79 (d, 1H, J = 7.5 Hz, H-6). 13C NMR 
(75 MHz, DMSO-d6)  -5.7 (CH3-Si), -5.6 (CH3-Si), -5.0 (2xCH3-
Si), -4.8 (CH3-Si), -4.6 (CH3-Si), 17.6 (tBu C(CH3)3), 17.7 (tBu 
C(CH3)3), 18.0 (tBu C(CH3)3), 25.6 (tBu CH3), 25.7 (tBu CH3), 25.8 
(tBu CH3), 61.9 (C-5’), 71.0 (C-3’), 75.2 (C-2’), 83.6 (C-4’), 87.8 
(C-5), 93.8 (C-1’), 140.4 (C-6), 155.1 (C-2), 165.4 (C-4). HRMS 
for C27H56N3O5Si3 ([M+H]+) calcd: 586.3522 found 586.3522. 
6.1.7 .5 .  2’ ,3’ ,5’ - tr i -O-TBDMS-uridine  (13f )  
1H NMR (300 MHz, DMSO-d6)  -0.02 (s, 3H, CH3-Si), 0.03 
(s, 3H, CH3-Si), 0.09 (s, 3H, CH3-Si), 0.09-0.11 (m, 9H, 3xCH3-
Si), 0.84 (s, 9H, tBu CH3), 0.89 (s, 9H, tBu CH3), 0.91 (s, 9H, tBu 
CH3), 3.68-3.75 (dd, 1H, J = 2.4 Hz and 11.4 Hz, H-5’a), 3.83-
3.90 (dd, 1H, J = 3.9 Hz and 11.4 Hz, H-5’b), 3.93-3.97 (m, 1H, 
H-4’), 4.05-4.09 (m, 1H, H-3’), 4.20-4.25 (m, 1H, H-2’), 5.64 (d, 
1H, J = 7.8 Hz, H-5), 5.82 (d, 1H, J = 5.7 Hz, H-1’), 7.77 (d, 1H, 
J = 8.1 Hz, H-6), 11.40 (s, 1H, NH). 13C NMR (75 MHz, DMSO-
d6)  -5.7 (CH3-Si), -5.6 (CH3-Si), -5.04 (CH3-Si), -5.0 (CH3-Si), -
4.8 (CH3-Si), -4.7 (CH3-Si), 17.6 (tBu C(CH3)3), 17.7 (tBu 
C(CH3)3), 18.0 (tBu C(CH3)3), 25.5 (tBu CH3), 25.7 (tBu CH3), 25.8 
(tBu CH3), 62.3 (C-5’), 71.7 (C-3’), 74.4 (C-2’), 84.7 (C-4’), 86.9 
(C-1’), 101.9 (C-5), 139.9 (C-6), 150.6 (C-2), 162.8 (C-4). HRMS 
for C27H53N2O6Si3 ([M-H]-) calcd: 585.3218 found 585.3218. 
6.1.8 .  General  procedure  for  5’ -desi ly lat ion  (14a-
f ) 4 5  
To a stirred solution of the persilylated nucleoside (200 mg) in 
THF (4 mL) was added aqueous TFA (2 mL, TFA:water 1:1) at 0 
oC. After stirring for 6 h at 0 oC, the reaction mixture was 
neutralized with saturated aqueous NaHCO3 and diluted with ethyl 
acetate (80 mL). The layers were separated and the organic phase 
was washed with water (10 mL) and brine (10 mL), dried over 
anhydrous Na2SO4, filtered and evaporated at reduced pressure. 
The residue was subjected to silica gel chromatography to provide 
the 2’,3’-disilylated products as a white solid in 90-99% yield. 
6.1.8 .1 .  1-( -D-r ibofuranosyl ) -4-n i t ro-2’ ,3’ -di -O-
TBDMS-benz imidazole  (14a )  
1H NMR (300 MHz, CDCl3)  -0.54 (s, 3H, CH3-Si), -0.09 (s, 
3H, CH3-Si), 0.15 (s, 6H, 2xCH3-Si), 0.72 (s, 9H, tBu CH3), 1.0 (s, 
9H, tBu CH3), 4.07-4.13 (m, 2H, H-5’a and H-5’b), 4.26 (bs, 1H, 
H-4’), 4.41 (d, 1H, J = 3.3 Hz, H-3’), 4.74-4.80 (dd, 1H, J = 4.8 
Hz and 7.2 Hz, H-2’), 6.03 (d, 1H, J = 6.6 Hz, H-1’), 7.43 (t, 1H, 
J = 8.4 Hz, H-6), 7.92 (d, 1H, J = 8.4 Hz, H-7), 8.22 (d, 1H, J = 
8.1 Hz, H-5), 9.19 (s, 1H, H-2). 13C NMR (75 MHz, CDCl3) -5.4 
(CH3-Si), -4.4 (2xCH3-Si), -4.3 (CH3-Si), 17.9 (tBu C(CH3)3), 18.3 
(tBu C(CH3)3), 25.8 (tBu CH3), 26.0 (tBu CH3), 62.0 (C-5’), 74.2 
(C-3’), 78.3 (C-2’), 87.9 (C-4’), 89.5 (C-1’), 117.3 (C-7), 120.0 
(C-5), 122.6 (C-6), 136.4 (C-9), 136.6 (C-8), 139.1 (C-4), 145.5 
(C-2). HRMS for C24H41N3O6Si2Na ([M+Na]+) calcd: 546.2426 
found 546.2420. 
6.1.8 .2 .  2’ ,3’ -d i-O-TBDMS-adenos ine  (14b ) 4 6  
1H NMR (300 MHz, DMSO-d6)  -0.38 (s, 3H, CH3-Si), -0.10 
(s, 3H, CH3-Si), 0.10 (s, 3H, CH3-Si), 0.12 (s, 3H, CH3-Si), 0.72 
(s, 9H, tBu CH3), 0.92 (s, 9H, tBu CH3), 3.55-3.63 (m, 1H, H-5’a), 
3.70-3.80 (m, 1H, H-5’b), 3.95-4.02 (m, 1H, H-4’), 4.29-4.35 (m, 
1H, H-3’), 4.75-4.83 (m, 1H, H-2’), 5.94 (d, 1H, J = 6.3 Hz, H-1’), 
8.35 (s, 1H, H-2), 8.60 (s, 1H, H-8). 13C NMR (75 MHz, DMSO-
d6) -5.7 (CH3-Si), -4.9 (CH3-Si), -4.8 (CH3-Si), -4.7 (CH3-Si), 
17.5 (tBu C(CH3)3), 17.8 (tBu C(CH3)3), 25.5 (tBu CH3), 25.7 (tBu 
CH3), 61.0 (C-5’), 72.6 (C-3’), 74.8 (C-2’), 86.9 (C-4’), 87.5 (C-
1’), 119.1 (C-5), 141.2 (C-8), 148.6 (C-4), 148.8 (C-2), 153.2 (C-
6). HRMS for C22H42N5O4Si2 ([M+H]+) calcd: 496.2770 found 
496.2771. 
6.1.8 .3 .  2’ ,3’ -d i-O-TBDMS-guanosine  (14c ) 4 3  
1H NMR (300 MHz, DMSO-d6) -0.36 (s, 3H, CH3-Si), -0.09 
(s, 3H, CH3-Si), 0.11 (s, 3H, CH3-Si), 0.13 (s, 3H, CH3-Si), 0.72 
(s, 9H, tBu CH3), 0.92 (s, 9H, tBu CH3), 3.53-3.64 (m, 1H, H-5’a), 
3.68-3.78 (m, 1H, H-5’b), 3.93-4.0 (m, 1H, H-4’), 4.27-4.32 (m, 
1H, H-3’), 4.73 (dd, 1H, J = 4.2 Hz and 6.6 Hz, H-2’), 5.24 (t, 1H, 
J = 6.0 Hz, 5’-OH), 5.90 (d, 1H, J = 6.9 Hz, H-1’), 8.11 (H-8), 8.39 
(NH). 13C NMR (75 MHz, DMSO-d6)  -5.7 (CH3-Si), -4.84 (CH3-
Si), -4.76 (CH3-Si), -4.7 (CH3-Si), 17.5 (tBu C(CH3)3), 17.8 (tBu 
C(CH3)3), 25.4 (tBu CH3), 25.7 (tBu CH3), 61.0 (C-5’), 72.7 (C-
3’), 75.2 (C-2’), 86.7 (C-4’), 86.8 (C-1’), 124.5 (C-5), 138.9 (C-
8), 146.0 (C-4), 148.2 (C-2), 156.5 (C-6). HRMS for 
C22H42N5O5Si2 ([M+H]+) calcd: 512.2718 found 512.2715. 
6.1.8 .4 .  2’ ,3’-d i-O-TBDMS-inosine  (14d )  
1H NMR (300 MHz, CDCl3)  -0.53 (s, 3H, CH3-Si), -0.13 (s, 
3H, CH3-Si), -.02 (s, 3H, CH3-Si), 0.01 (2s, 6H, 2xCH3-Si), 0.74 
(s, 9H, tBu, CH3), 0.94 (s, 9H, tBu, CH3), 3.71 (d, 1H, J = 12.6 Hz, 
H-5’), 3.94 (d, 1H, J = 12.9 Hz, H-5’), 4.15 (bs, 1H, H-4’), 4.37 
(d, 1H, J = 4.2 Hz, H-3’), 4.82-4.92 (m, 1H, H-2’), 5.78 (d, 1H, J 
= 7.5 Hz, H-1’), 7.90 (s, 1H, H-2), 8.43 (s, 1H, H-8). 13C NMR (75 
MHz, CDCl3)  -5.7 (CH3-Si), -4.52 (CH3-Si), -4.47 (CH3-Si), -4.4 
(CH3-Si), 17.9 (tBu C(CH3)3), 18.2 (tBu C(CH3)3), 25.8 (tBu CH3), 
25.9 (tBu CH3), 62.9 (C-5’), 73.9 (C-3’), 74.8 (C-2’), 89.2 (C-4’), 
91.0 (C-1’), 126.7 (C-5), 140.9 (C-8), 146.3 (C-2), 147.9 (C-4), 
159.6 (C-6). HRMS for C22H41N4O5Si2 ([M+H]+) calcd: 497.2610 
found 497.2608. 
6.1.8 .5 .  2’ ,3’-d i-O-TBDMS-cyt id ine  (14e )  
1H NMR (600 MHz, DMSO-d6)  -0.01 (s, 3H, CH3-Si), 0.01 
(s, 3H, CH3-Si), 0.06 (s, 3H, CH3-Si), 0.08 (s, 3H, CH3-Si), 0.82 
(s, 9H, tBu CH3), 0.88 (s, 9H, tBu CH3), 3.51-3.56 (m, 1H, H-5’a), 
3.65-3.70 (m, 1H, H-5’b), 3.86 (q, 1H, J = 3.6 Hz, H-4’), 4.10 (t, 
1H, J = 4.2 Hz, H-3’), 4.19 (t, 1H, J = 4.8 Hz, H-2’), 5.19-5.21 (m, 
1H, 5’-OH) 5.75 (d, 1H, J = 7.2 Hz, H-5) 5.77 (d, 1H, J = 4.8 Hz, 
H-1’) 7.20-7.35 (m, 2H, NH2), 7.91 (d, 1H, J = 7.2 Hz, H-6). 13C 
NMR (150 MHz, DMSO-d6) -4.9 (2xCH3-Si), -4.8 (CH3-Si), -
4.6 (CH3-Si), 17.7 (tBu C(CH3)3), 17.8 (tBu C(CH3)3), 25.7 (tBu 
 
 
 
 
 
 
 
 
CH3), 25.8 (tBu CH3), 60.1 (C-5’), 71.4 (C-3’), 74.9 (C-2’), 84.5 
(C-4’), 88.3 (C-5), 94.0 (C-1’), 141.5 (C-6), 155.0 (C-2), 165.2 (C-
4). HRMS for C22H42N3O5Si2 ([M-H]-) calcd: 472.2657 found 
472.2652. 
6.1.8 .6 .  2’ ,3’-d i-O-TBDMS-uridine  (14f ) 4 6  
1H NMR (300 MHz, DMSO-d6)  -0.03 (s, 3H, CH3-Si), 0.02 
(s, 3H, CH3-Si), 0.08 (s, 3H, CH3-Si), 0.09 (s, 3H, CH3-Si), 0.83 
(s, 9H, tBu CH3), 0.88 (s, 9H, tBu CH3), 3.52-3.70 (m, 2H, H-5’a 
and H-5’b), 3.85-3.90 (m, 1H, 5’-OH), 4.10-4.17 (m, 1H, H-3’), 
4.25 (t, 1H, J = 5.7 Hz, H-2’), 5.24 (d, 1H, J = 4.8 Hz, H-4’) 5.68 
(d, 1H, J = 8.4 Hz, H-5) 5.81 (d, 1H, J = 6.0 Hz, H-1’) 7.93 (d, 1H, 
J = 8.1 Hz, H-6), 11.34 (s, 1H, NH). 13C NMR (75 MHz, DMSO-
d6) -5.0 (CH3-Si), -4.9 (CH3-Si), -4.8 (CH3-Si), -4.6 (CH3-Si), 
17.6 (tBu C(CH3)3), 17.7 (tBu C(CH3)3), 25.59 (tBu CH3), 25.64 
(tBu CH3), 60.4 (C-5’), 71.9 (C-3’), 74.6 (C-2’), 85.5 (C-4’), 86.9 
(C-1’), 102.0 (C-5), 140.3 (C-6), 150.8 (C-2), 163.0 (C-4). HRMS 
for C21H39N2O6Si2 ([M-H]-) calcd: 471.2352 found 471.2343. 
6.1.9. General procedure for synthesis of the respective 5’-O-
sulfamoyl nucleosides (15a-f)Formic acid (2.5 mmol) was added 
to ice cooled chlorosulfonyl isocyanate (2.5 mmol) and allowed to 
stir at 0 oC for 5 min. The resulting solid was dissolved in dry 
acetonitrile (2 mL) and cooled to 0 oC. The obtained sulfamoyl 
chloride was then added to an ice cooled solution of the respective 
nucleoside (1 mmol) in dimethyl acetamide (5 mL) and allowed to 
stir at room temperature for 1 h. After 1 h, TEA (1.5 mL, excess) 
was added and stirring was continued for an additional 10 min. 
Subsequently, methanol (2 mL) was added and the mixture was 
stirred for an additional 15 min. Finally, the solvent was 
evaporated to dryness and the residue was dissolved in ethyl 
acetate and washed with saturated NaHCO3. The organic layer was 
further washed with water and brine. The organic layer was 
collected, dried over Na2SO4, filtered and evaporated. The residue 
was subjected to silica gel chromatography to afford 
sulfamoylated nucleoside in 63-80% yield. 
6.1.9 .1 .  1-(2’ ,3’ -di -O-TBDMS)-5’-O-sul famoyl - -
D-r ibofuranosyl ) -4-ni t ro-benz imidazole  (15a )  
1H NMR (500 MHz, CDCl3)  -0.50 (s, 3H, CH3-Si), -0.10 (s, 
3H, CH3-Si), 0.13 (s, 6H, 2xCH3-Si), 0.71 (s, 9H, tBu CH3), 0.95 
(s, 9H, tBu CH3), 4.31-4.36 (m, 2H, H-5’a and H-5’b), 4.41-4.45 
(m, 2H, H-4’, H-3’), 4.55-4.59 (dd, 1H, J = 2.5 Hz, 11.0 Hz, H-
2’), 5.97 (d, 1H, J = 6.5 Hz, H-1’), 6.68 (bs, 2H, NH2), 7.40 (t, 1H, 
J = 8.0 Hz, H-6), 7.85 (d, 1H, J = 8.0 Hz, H-7), 8.15 (d, 1H, J = 
8.0 Hz, H-5), 8.59 (s, 1H, H-2). 13C NMR (125 MHz, CDCl3)  -
6.4 (CH3-Si), -5.6 (CH3-Si), -5.5 (CH3-Si), -5.3 (CH3-Si), 16.9 (tBu 
C(CH3)3), 17.1 (tBu C(CH3)3), 24.8 (tBu CH3), 25.0 (tBu CH3), 67.9 
(C-5’), 71.9 (C-2’), 76.0 (C-3’), 82.9 (C-4’), 88.0 (C-1’), 116.5 (C-
7), 119.1 (C-5), 121.8 (C-6 ),134.9 (C-9), 135.8 (C-8), 138.1 (C-
4), 143.7 (C-2). HRMS for C24H43N4O8SSi2 ([M+H]+) calcd: 
603.2334 found 603.2325. 
6.1.9 .2 .  2’ ,3’-d i-O-TBDMS-5’-O-sul famoyl-
adenosine (15b )  
1H NMR (300 MHz, DMSO-d6)  -0.37 (s, 3H, CH3-Si), -0.08 
(s, 3H, CH3-Si), 0.13 (s, 3H, CH3-Si), 0.15 (s, 3H, CH3-Si), 0.71 
(s, 9H, tBu CH3), 0.93 (s, 9H, tBu CH3), 4.15-4.21 (m, 1H, H-3’), 
4.27-4.34 (m, 1H, H-2’), 4.36-4.44 (m, 2H, H-5’a and H-5’b), 
4.94-4.94 (dd, 1H, J = 4.5 Hz, 6.6 Hz, H-4’), 5.96 (d, 1H, J = 6.9 
Hz, H-1’), 7.31 (s, 2H, NH2), 7.64 (s, 2H, NH2), 8.16 (s, 1H, H-8), 
8.36 (s, 1H, H-2). 13C NMR (75 MHz, DMSO-d6)  -5.6 (CH3-Si), 
-4.9 (CH3-Si), -4.8 (CH3-Si), -4.7 (CH3-Si), 17.5 (tBu C(CH3)3), 
17.7 (tBu C(CH3)3), 25.4 (tBu CH3), 25.7 (tBu CH3), 68.0 (C-5’), 
72.4 (C-2’), 73.7 (C-3’), 82.8 (C-4’), 87.0 (C-1’), 119.3 (C-5), 
139.8 (C-8), 149.4 (C-4), 152.7 (C-2), 156.1 (C-6). HRMS for 
C22H43N6O6SSi2 ([M+H]+) calcd: 575.2498 found 575.2530. 
6.1.9 .3 .  2’ ,3’-d i-O-TBDMS-5’-O-sul famoyl-
guanosine (15c )  
1H NMR (300 MHz, DMSO-d6)  -0.28 (s, 3H, CH3-Si), -0.06 
(s, 3H, CH3-Si), 0.12 (s, 3H, CH3-Si), 0.14 (s, 3H, CH3-Si), 0.73 
(s, 9H, tBu CH3), 0.92 (s, 9H, tBu CH3), 4.12-4.17 (m, 1H, H-3’), 
4.21-4.35 (m, 3H, H-2’, H-5’a and H-5’b), 4.75-4.81 (dd, 1H, J = 
4.5 Hz, 7.2 Hz, H-4’), 5.76 (d, 1H, J = 7.5 Hz, H-1’), 6.47 (bs, 2H, 
SONH2), 7.66 (s, 2H, 2-NH2), 7.91 (s, 1H, H-8), 10.69 (s, 1H, NH). 
13C NMR (75 MHz, DMSO-d6)  -5.6 (CH3-Si), -4.9 (CH3-Si), -
4.7 (2xCH3-Si), 17.5 (tBu C(CH3)3), 17.7 (tBu C(CH3)3), 25.5 (tBu 
CH3), 25.7 (tBu CH3), 68.1 (C-5’), 72.7 (C-2’), 74.0 (C-3’), 83.0 
(C-4’), 85.8 (C-1’), 116.8 (C-5), 135.6 (C-8), 151.5 (C-4), 153.7 
(C-2), 156.7 (C-6). HRMS for C22H43N6O7SSi2 ([M+H]+) calcd: 
591.2447 found 591.2455. 
6.1.9 .4 .  2’ ,3’-d i-O-TBDMS-5’-O-sul famoyl-
inos ine (15d )  
1H NMR (300 MHz, CDCl3)  -0.33 (s, 3H, CH3-Si), -0.08 (s, 
3H, CH3-Si), 0.11 (s, 3H, CH3-Si), 0.15 (s, 3H, CH3-Si),0.76 (s, 
9H, tBu CH3), 0.94 (s, 9H, tBu CH3), 4.30-4.42 (m, 2H, H-5’a and 
H-5’b), 4.48-4.52 (m, 1H, H-4’), 4.65-4.75 (m, 1H, H-3’), 4.75-
4.80  (m, 1H, H-2’), 5.82 (d, 1H, J = 5.4 Hz, H-1’), 7.01 (bs, 2H, 
NH2), 8.01 (s, 1H, H-8), 8.42 (s, 1H, H-2). 13C NMR (75 MHz, 
CDCl3)  -5.1 (CH3-Si), -4.7 (CH3-Si), -4.6 (CH3-Si), -4.3 (CH3-
Si), 17.9 (tBu C(CH3)3), 18.2 (tBu C(CH3)3), 25.8 (tBu CH3), 26.0 
(tBu CH3), 69.0 (C-5’), 72.3 (C-2’), 74.8 (C-3’), 83.3 (C-4’), 90.0 
(C-1’), 124.8 (C-5), 140.8 (C-8), 146.1 (C-2), 148.2 (C-4), 158.3 
(C-6). HRMS for C22H41N5O7SSi2 ([M+H]+) calcd: 576.2338 
found 576.2347. 
6.1.9 .5 .  2’ ,3’-d i-O-TBDMS-5’-O-sul famoyl-
cy t id ine  (15e )  
1H NMR (300 MHz, DMSO-d6)  0.00 (s, 3H, CH3-Si), 0.02 (s, 
3H, CH3-Si), 0.08 (s, 3H, CH3-Si), 0.10 (s, 3H, CH3-Si),0.83 (s, 
9H, tBu CH3), 0.88 (s, 9H, tBu CH3), 4.04-4.18 (m, 3H, H-5’a, H-
5’b and H-4’), 4.22-4.32 (m, 2H, H-2’ and H-3’), 5.73-5.80 (m, 
2H, H-5 and H-1’), 7.21-7.38 (m, 2H, SONH2), 7.63 (d, 1H, J = 
7.5 Hz, H-6), 7.68 (s, 2H, NH2). 13C NMR (75 MHz, , DMSO-d6) 
 -5.0 (CH3-Si), -4.9 (CH3-Si), -4.8 (CH3-Si), -4.6 (CH3-Si), 17.6 
(tBu C(CH3)3), 17.7 (tBu C(CH3)3), 25.67 (tBu CH3), 25.69 (tBu 
CH3), 67.5 (C-5’), 71.2 (C-3’), 74.0 (C-2’), 81.0 (C-4’), 88.9 (C-
5), 94.3 (C-1’), 141.1 (C-6), 154.8 (C-2), 165.2 (C-4). HRMS for 
C21H43N4O7SSi2 ([M+H]+) calcd: 551.2385 found 551.2380. 
 
 
 
 
 
 
 
 
6.1.9 .6 .  2’ ,3’-d i-O-TBDMS-5’-O-sul famoyl-
ur id ine (15f )  
1H NMR (300 MHz, CDCl3)  0.07 (s, 3H, CH3-Si), 0.08 (s, 
3H, CH3-Si), 0.10 (s, 3H, CH3-Si), 0.11 (s, 3H, CH3-Si),0.88 (s, 
9H, tBu CH3), 0.91 (s, 9H, tBu CH3), 4.12 (t, 1H, J = 4.2 Hz, H-
5’a) 4.24 (q, 1H, J = 3.9 Hz, H-4’), 4.28 (dd, 1H, J = 3.6 Hz and 
11.1 Hz, H-5’b), 4.48-4.54 (m, 2H, H-2’ and H-3’), 5.53 (d, 1H, J 
= 4.5 Hz, H-1’), 5.62 (bs, 2H, SONH2), 5.77 (d, 1H, J = 8.1 Hz, H-
5), 7.50 (d, 1H, J = 8.1 Hz, H-6), 9.70 (bs, 1H, NH). 13C NMR (75 
MHz, CDCl3)  -5.8 (CH3-Si), -5.59 (CH3-Si), -5.56 (CH3-Si), -5.2 
(CH3-Si), 17.10 (tBu C(CH3)3), 17.15 (tBu C(CH3)3), 24.90 (tBu 
CH3), 24.93 (tBu CH3), 67.4 (C-5’), 70.5 (C-3’), 72.6 (C-2’), 81.1 
(C-4’), 92.1 (C-1’), 101.6 (C-5), 141.1 (C-6), 149.7 (C-2), 162.7 
(C-4). HRMS for C21H41N3O8SSi2Na ([M+Na]+) calcd: 574.2045 
found 574.2043. 
6.1.10.  General  procedure  for  synthes is  o f  5’ -O-(N-
L- iso leucyl ) -su l famoyl  nucleos ides (16a-f )  
To a solution of the respective 2’,3’-di-O-(tert-
butyldimethylsilyl)-5’-O-sulfamoyl nucleoside (1.0 mmol) and 
N-Boc-L-isoleucine N-hydroxysuccinimide ester (1.1 equiv) in 
DMF (3 mL) was added DBU (1.1 equiv) and the reaction mixture 
was stirred at rt for 6-8h. Next, the volatiles were removed in vacuo 
and the residue was purified by silica gel chromatography (Et3N 
1%, MeOH 2.5-10% in CH2Cl2). 
The coupled product was next treated with TFA/H2O (5/2 v/v) 
for 2 h at rt, after which the volatiles were evaporated and 
coevaporated twice with EtOH and once with EtOH and Et3N (2 
mL), to neutralize any remaining acid. The compound was 
carefully dried and dissolved in THF (2 mL) and Et3N.3HF (0.5 
mL). After 3 h, another 0.4 mL of Et3N.3HF was added and the 
reaction mixture was stirred further for 22 h. The reaction mixture 
was evaporated and the residue was purified by flash 
chromatography (5 to 50% CH2Cl2:MeOH) and finally by HPLC 
using PLRP-S 100 Å column and acetonitrile:water as mobile 
phase to yield isoleucyl-sulfamoyl nucleoside as white solid in 28-
65% yield. 
6.1.10.1.  1-[5’-O-(N-L- isoleucyl -sul famoyl- -D-
r ibofuranosyl )] -4-ni t ro-benz imidazole  (16a )  
1H NMR (500 MHz, D2O)  0.74 (t, 3H, J = 10.0 Hz, Ile--
CH3), 0.88 (d, 3H, J = 10.0 Hz, Ile--CH3), 1.05-1.15 (m, 1H, Ile-
-CH2 Ha), 1.32-1.41 (m, 1H, Ile--CH2 Hb), 1.79-1.85 (m, 1H, 
Ile--CH), 3.46 (d, 1H, J = 5.0 Hz, Ile--CH), 4.38-4.45 (m, 2H, 
H-5’a and H-5’b), 4.45-4.50 (m, 2H, H-3’ and H-4’), 4.61 (t, 1H, 
J = 5.0 Hz, H-2’), 6.09 (d, 1H, J = 5.0 Hz, H-1’), 7.44 (t, 1H, J = 
10.0 Hz, H-6), 8.03 (d, 1H, J = 10.0 Hz, H-7), 8.12 (d, 1H, J = 10.0 
Hz, H-5) 8.60 (s, 1H, H-2). 13C NMR (75 MHz, D2O)  10.4 (Ile-
-CH3), 14.4 (Ile--CH3), 23.6 (Ile--CH2), 37.0 (Ile--CH), 60.3 
(Ile--CH), 67.7 (C-5’), 69.8 (C-3’), 73.5 (C-2’), 82.5 (C-4’), 88.8 
(C-1’), 118.7 (C-7), 120.2 (C-5), 123.0 (C-6), 134.5 (C-9), 135.6 
(C-8), 137.3 (C-4), 145.0 (C-2), 178.4 (C=O, Ile). HRMS for 
C18H24N5O9S ([M-H]-) calcd: 486.1300 found 486.1301. 
6.1.10.2.  5’-O-(N-L- iso leucyl ) -sul famoyl-
adenosine (16b )  
1H NMR (300 MHz, D2O)  0.87 (t, 3H, J = 7.5 Hz, Ile--CH3), 
0.98 (d, 3H, J = 6.9 Hz, Ile--CH3), 1.02-1.28 (m, 1H, Ile--CH2 
Ha), 1.40-1.53 (m, 1H, Ile--CH2 Hb), 1.95-2.07 (m, 1H, Ile--
CH), 3.76 (d, 1H, J = 4.2 Hz, Ile--CH), 4.43-4.51 (m, 3H, H-5’a, 
H-5’b and H-4’), 4.56 (t, 1H, J = 5.1 Hz, H-3’), 4.75-4.78 (m, 1H, 
merged with D2O peak, H-2’), 6.13 (d, 1H, J = 5.1 Hz, H-1’), 8.24 
(s, 1H, H-8), 8.42 (s, 1H, H-2). 13C NMR (75 MHz, D2O)  11.5 
(Ile--CH3), 15.1 (Ile--CH3), 24.7 (Ile--CH2), 37.0 (Ile--CH), 
60.7 (Ile--CH), 68.9 (C-5’), 70.8 (C-3’), 74.7 (C-2’), 82.9 (C-4’), 
87.9 (C-1’), 119.1 (C-5), 140.4 (C-8), 149.5 (C-4), 153.1 (C-2), 
155.8 (C-6), 175.6 (C=O, Ile). HRMS for C16H24N7O7S ([M-H]-) 
calcd: 458.1463 found 458.1461. 
6.1.10.3.  5’-O-(N-L- iso leucyl ) -sul famoyl-
guanosine (16c )  
1H NMR (600 MHz, D2O)  0.83 (t, 3H, J = 7.2 Hz, Ile--CH3), 
0.94 (d, 3H, J = 7.2 Hz, Ile--CH3), 1.01-1.19 (m, 1H, Ile--CH2 
Ha), 1.34-1.43 (m, 1H, Ile--CH2 Hb), 1.92-1.99 (m, 1H, Ile--
CH), 3.89 (d, 1H, J = 4.2 Hz, Ile--CH), 4.35-4.40 (m, 3H, H-5’a, 
H-5’b and H-4’), 4.50 (t, 1H, J = 4.2 Hz, H-3’), 4.70-4.75 (m, 1H, 
H-2’), 5.92 (d, 1H, J = 6.0 Hz, H-1’), 8.03 (s, 1H, H-8). 13C NMR 
(125 MHz, D2O)  10.5 (Ile--CH3), 14.1 (Ile--CH3), 23.7 (Ile--
CH2), 36.0 (Ile--CH), 59.7 (Ile--CH), 68.0 (C-5’), 69.8 (C-3’), 
73.2 (C-2’), 81.9 (C-4’), 86.6 (C-1’), 115.9 (C-5), 137.1 (C-8), 
151.4 (C-4), 153.6 (C-2), 158.7 (C-6), 174.7 (C=O, Ile). HRMS 
for C16H24N7O8S ([M-H]-) calcd: 474.1412 found 474.1407. 
6.1.10.4.  5’-O-(N-L- isoleucyl ) -sul famoyl- inos ine  
(16d )  
1H NMR (300 MHz, D2O)  0.74 (t, 3H, J = 7.5 Hz, Ile--CH3), 
0.86 (d, 3H, J = 7.2 Hz, Ile--CH3), 1.01-1.17 (m, 1H, Ile--CH2 
Ha), 1.25-1.40 (m, 1H, Ile--CH2 Hb), 1.82-1.95 (m, 1H, Ile--
CH), 3.62 (d, 1H, J = 4.2 Hz, Ile--CH), 4.29-4.38 (m, 3H, H-5’a, 
H-5’b and H-4’), 4.43 (t, 1H, J = 4.2 Hz, H-3’), 4.62-4.70 (m, 1H, 
merged with solvent peak, H-2’), 6.02 (d, 1H, J = 5.1 Hz, H-1’), 
8.11 (s, 1H, H-8), 8.27 (s, 1H, H-2). 13C NMR (75 MHz, D2O)  
10.6 (Ile--CH3), 14.1 (Ile--CH3), 23.7 (Ile--CH2), 36.1 (Ile--
CH), 59.8 (Ile--CH), 67.8 (C-5’), 69.9 (C-3’), 73.9 (C-2’), 82.1 
(C-4’), 87.4 (C-1’), 123.4 (C-5), 139.2 (C-8), 146.1 (C-2), 148.4 
(C-4), 158.5 (C-6), 175.0 (C=O, Ile). HRMS for C16H23N6O8S 
([M-H]-) calcd: 459.1303 found 459.1304. 
6.1.10.5.  5’-O-(N-L- iso leucyl ) -sul famoyl-cyt idine  
(16e )  
1H NMR (300 MHz, D2O)  0.91 (t, 3H, J = 7.5 Hz, Ile--CH3), 
1.02 (d, 3H, J = 7.2 Hz, Ile--CH3), 1.17-1.33 (m, 1H, Ile--CH2 
Ha), 1.41-1.56 (m, 1H, Ile--CH2 Hb), 1.99-2.10 (m, 1H, Ile--
CH), 3.76 (d, 1H, J = 4.2 Hz, Ile--CH), 4.23-4.37 (m, 4H, H-5’a, 
H-5’b H-4’and H-3’), 4.44-4.51 (m, 1H, H-2’), 5.95 (d, 1H, J = 
3.3 Hz, H-1’), 6.10 (d, 1H, J = 7.5 Hz, H-5) 7.83 (d, 1H, J = 7.8 
Hz,  H-6). 13C NMR (75 MHz, D2O)  10.6 (Ile--CH3), 14.2 (Ile-
-CH3), 23.8 (Ile--CH2), 36.1 (Ile--CH), 59.8 (Ile--CH), 67.6 
(C-5’), 68.9 (C-3’), 73.7 (C-2’), 80.9 (C-4’), 89.5 (C-5), 96.1 (C-
1’), 141.0 (C-6), 157.3 (C-2), 165.8 (C-4), 174.8 (C=O, Ile). 
HRMS for C15H26N5O8S ([M+H]+) calcd: 436.1496 found 
436.1495. 
 
 
 
 
 
 
 
 
6.1.10.6.  5’-O-(N-L- isoleucyl ) -sul famoyl-ur id ine  
(16f )  
1H NMR (300 MHz, D2O)  0.93 (t, 3H, J = 7.5 Hz, Ile--CH3), 
1.02 (d, 3H, J = 6.9 Hz, Ile--CH3), 1.18-1.34 (m, 1H, Ile--CH2 
Ha), 1.42-1.56 (m, 1H, Ile--CH2 Hb), 1.98-2.11 (m, 1H, Ile--
CH), 3.75 (d, 1H, J = 3.9 Hz, Ile--CH), 4.38-4.48 (m, 5H, H-5’a, 
H-5’b, H-4’ H-3’, H-2’), 5.92 (m, 2H, H-1’ and H-5), 7.84 (d, 1H, 
J = 8.1 Hz, H-6). 13C NMR (75 MHz, D2O)  10.7 (Ile--CH3), 
14.2 (Ile--CH3), 23.8 (Ile--CH2), 36.1 (Ile--CH), 59.7 (Ile--
CH), 67.7 (C-5’), 69.2 (C-3’), 73.3 (C-2’), 81.4 (C-4’), 88.5 (C-
1’), 102.2 (C-5), 141.2 (C-6), 151.3 (C-2), 165.8 (C-4), 174.8 
(C=O, Ile). HRMS for C15H23N4O9S ([M-H]-) calcd: 435.1191 
found 435.1192. 
6.1.11.  5’-O-(N-L- iso leucyl ) -sul famoyl-1 ,3-dideaza-
adenosine (16g )  
To a solution of 16a (50 mg, 0.1 mmol) in dry methanol (5 mL) 
was added Pd/C (10% w/w, 20 mg) and the mixture was stirred 
under H2 atmosphere at room temperature for 7 h. Next, the 
catalyst was filtered off and the solvent was evaporated to dryness. 
The product was purified by silica gel column chromatography and 
finally by HPLC to yield 19 mg (0.04 mmol, 40%) of title 
compound as faint brown solid. 
1H NMR (500 MHz, D2O)  0.80 (t, 3H, J = 7.5 Hz, Ile--CH3), 
0.95 (d, 3H, J = 7.0 Hz, Ile--CH3), 1.12-1.24 (m, 1H, Ile--CH2 
Ha), 1.37-1.46 (m, 1H, Ile--CH2 Hb), 1.95-2.02 (m, 1H, Ile--
CH), 3.71 (d, 1H, J = 4.0 Hz, Ile--CH), 4.41-4.46 (m, 3H, H-5’a, 
H-5’b, H-4’), 4.48-4.51 (m,1H, H-3’), 4.67 (t, 1H, J = 6.0 Hz, H-
2’), 6.04 (d, 1H, J = 6.5 Hz, H-1’), 6.78 (d, 1H, J = 7.5 Hz, H-1), 
7.17 (d, 1H, J = 7.5 Hz, H-3), 7.23 (t, 1H, J = 8.0 Hz, H-2), 8.34 
(s, 1H, H-8). 13C NMR (125 MHz, D2O)  10.5 (Ile--CH3), 14.1 
(Ile--CH3), 23.7 (Ile--CH2), 36.0 (Ile--CH), 59.8 (Ile--CH), 
68.1 (C-5’), 69.7 (C-3’), 72.8 (C-2’), 82.0 (C-4’), 88.2 (C-1’), 
101.7 (C-3), 108.3 (C-1), 124.7 (C-2), 132.1 (C-5), 133.0 (C-6), 
137.5 (C-4), 140.5 (C-8), 174.8 (C=O Ile). HRMS for 
C18H26N5O7S ([M-H]-) calcd: 456.1558 found 456.1560. 
6.1.12.  General  procedure  for  synthes is  o f  
nucleos ide su l famate-hexapept idy l  conjugates  (17a-
g )  
The peptide formyl-methionyl-arginyl(2,2,4,6,7-pentamethyl 
dihydrobenzofuran-5-sulfonyl)-threonyl(tBu)-glycyl-asparaginyl-
(trityl)-alanyl-OH was synthesized on a 2-chlorotrityl chloride 
resin using standard Fmoc-based solid phase peptide chemistry. 
The protected hexapeptide was cleaved from the resin using a 
mixture of HOAc/trifluoroethanol/DCM (1/1/8, v/v) in 30 min. 
Following RP-HPLC purification, the peptide (20 mg, 16.13 µmol, 
1.0 eq.) and HOBt (9 mg, 64.52 µmol, 4.0 eq.) were dissolved in 
DMF (500 µL) and DIC (10 µL, 64.52 µmol, 4.0 eq.) was added. 
This mixture was stirred for 1 h at rt under argon atmosphere. 
Following addition of DIPEA (7.5 µL, 40.33 µmol, 2.5 eq.), the 
mixture was added to the nucleoside sulfamate analogue 16a-g 
(32.26 µmol, 2.0 eq.) and stirred for 16 h at rt under argon. Next, 
the volatiles were evaporated and the residue was taken up in a 
mixture of CH3CN/water. This was purified on a PoraPak Rxn RP 
6 cc Vac Cartridge 80m particle (Waters®) column with a CH3CN 
gradient of 25 to 100% in water). The fractions containing the 
product were evaporated and the protected conjugate was 
subsequently deprotected using a mixture of 90% TFA, 7.5% H2O 
and 2.5% thioanisole. The reaction mixture was poured in chilled 
diethyl ether and centrifuged. Supernatant was decanted and the 
residue was re-suspended in chilled diethyl ether and centrifuged. 
A small amount of TEA (500 L) was added for final washing. 
The product was dissolved in CH3CN/water and purified by RP-
HPLC (solvent A: 25 mM TEAB in H2O; solvent B: 25 mM TEAB 
in CH3CN; see supporting file for HPLC analysis of all final 
compounds). Overall yield for coupling, deprotection and tedious 
HPLC purification is generally low and affords about 6-12% yield. 
6.1.12.1.  fMRTGNAI-S(4-ni t robenz imidazole)  
(17a )  
1H NMR (600 MHz, D2O)  0.73 (t, 3H, J = 7.2 Hz, Ile--CH3), 
0.81 (d, 3H, J = 6.6 Hz, Ile--CH3), 1.00-1.10 (m, 1H, Ile--CH2, 
Ha), 1.14-1.21 (m, Thr--CH3, TEA-CH3), 1.27-1.39 (d+m, 4H, J 
= 7.2 Hz, Ala--CH3 and Ile--CH2, Hb), 1.55 (m, 2H, Arg--CH2), 
1.67-1.88 (m, 3H, Ile -CH and 2H, Arg--CH2), 1.95-2.07 (m+s, 
5H, Met--CH2 and Met-SCH3), 2.53 (m, 2H, Met--CH2), 2.37 
(dd, 1H, J = 8.4 Hz and 15.6 Hz, Asn--CH2, Ha), 2.78 (dd, 1H, J 
= 4.8 Hz, and 16.2 Hz, Asn--CH2, Hb), 3.00 (m, TEA-CH2), 3.10 
(m, 2H, Arg--CH2), 3.87 (d, 1H, J = 16.9 Hz,  Gly--CH2, Ha), 
3.94-4.00 (m, 2H,  Ile--CH and Gly--CH2, Hb), 4.19-4.28 (m, 
2H, Thr--CH, Ala--CH), 4.31-4.41 (m, 4H, Thr--CH, Arg--
CH and H-5’a and H-5’b), 4.42-4.46 (m, 2H, H-3’and H-4’), 4.49 
(dd, 1H, J = 5.9 Hz and 8.2 Hz, Met--CH), 4.64-4.68 (m, 2H, H-
2’ and Asn--CH), 6.13 (d, 1H, J = 6.7 Hz, H-1’), 7.54 (t, 1H, J = 
8.3 Hz, H-6), 8.08 (s, 1H, CHO), 8.16 (d, 1H, J = 8.3 Hz,  H-7), 
8.26 (d, 1H, J = 8.3 Hz,  H-5), 8.68 (s, 1H, H-2). 13C NMR (150 
MHz, D2O) -CH3Ile--CH3), 13.8 (Met-SCH3), 
14.7 (Ile--CH3Ala--CH3Thr--CH3 24.0 (Ile--
CH2), 24.1 (Arg--CH2), 27.7 (Arg--CH2), 28.7 (Met--CH2), 
30.1 (Met--CH2), 35.9 (Asn--CH2), 36.6 (Ile--CH), 40.1 (Arg-
-CH2), 42.2 (Gly--CH2), 45.6 (TEA-CH2), 49.5 (Ala--CH), 
49.9 (Asn--CH), 51.1 (Met--CH), 53.0 (Arg--CH), 58.6 (Thr-
-CH), 60.2 (Ile--CH), 66.9 (Thr--CH), 68.0 (C-5’), 70.0 (C-
3’), 73.4 (C-2’), 82.8 (C-4’), 88.7 (C-1’), 119.0 (C-7), 120.5 (C-
5), 123.2 (C-6), 134.8 (C-8), 135.9 (C-9), 137.7 (C-4), 145.4 (C-
2), 156.2 (Arg-C), 163.9 (CHO), 170.9 (Gly-CO), 171.8 (Asn-
CO), 172.0 (Thr-CO), 173.0 (Met-CO), 173.3 (Arg-CO), 174.0 
(Ala-CO and Asn-C), 179.1 (Ile-CO). HRMS for C43H66N15O18S2 
([M-H]-) calcd: 1144.4158 found 1144.4150. 
6.1.12.2.  fMRTGNAI-SA (17b )  
1H NMR (600 MHz, D2O)  0.85 (t, 3H, J = 7.2 Hz, Ile--CH3), 
0.90 (d, 3H, J = 6.6 Hz, Ile--CH3), 1.13-1.24 (m, Thr--CH3, 
TEA-CH3 and Ile--CH2, Ha), 1.36 (d, 3H, J = 7.2 Hz, Ala--CH3), 
1.43-1.52 (m, 1H, Ile--CH2, Hb), 1.61 (m, 2H, Arg--CH2), 1.71-
1.92 (m, 3H, Ile -CH and 2H, Arg--CH2), 1.96-2.08 (m+s, 5H, 
Met--CH2 and Met-SCH3), 2.55 (m, 2H, Met--CH2), 2.70 (dd, 
1H, J = 8.4 Hz and 15.6 Hz, Asn--CH2, Ha), 2.79 (dd, 1H, J = 4.8 
Hz, and 16.2 Hz, Asn--CH2, Hb), 3.08-3.21 (m, TEA-CH2 and 
Arg--CH2), 3.97 (d, 1H, J = 16.9 Hz,  Gly--CH2, Ha), 3.98 (d, 
1H, J = 16.9 Hz,  Gly--CH2, Hb), 4.06 (d, 1H, J = 6.9 Hz, Ile--
 
 
 
 
 
 
 
 
CH), 4.21 (m, 1H, Thr--CH ), 4.26-4.46 (m, 7H, Ala--CH, Thr-
-CH, Arg--CH, H-3’, H-4’  and H-5’a and H-5’b), 4.50 (dd, 1H, 
J = 5.9 Hz, and 8.2 Hz, Met--CH), 4.67 (dd, 1H, J = 5.2 Hz and 
8.9 Hz, Asn--CH), 4.72 (m, 1H, H-2’), 6.09 (d, 1H, J = 5.9 Hz, 
H-1’), 8.08 (s, 1H, CHO) , 8.22 (s, 1H, H-2), 8.42 (s, 1H, H-8). 13C 
NMR (150 MHz, D2O) -CH3Ile--CH3), 13.8 
(Met-SCH3), 14.4 (Ile--CH3Ala--CH3Thr--
CH3 24.1 (Ile--CH2), 24.3 (Arg--CH2), 27.6 (Arg--CH2), 28.7 
(Met--CH2), 30.1 (Met--CH2), 35.4 (Asn--CH2), 35.9 (Ile--
CH), 40.1 (Arg--CH2), 42.1 (Gly--CH2), 46.3 (TEA-CH2), 49.5 
(Ala--CH), 50.0 (Asn--CH), 51.1 (Met--CH), 53.2 (Arg--
CH), 58.8 (Thr--CH), 60.4 (Ile--CH), 66.9 (Thr--CH), 68.0 
(C-5’), 70.2 (C-3’), 73.7 (C-2’), 82.8 (C-4’), 86.5 (C-1’), 139.4 (C-
8), 148.8 (C-4), 152.7 (C-2), 155.2 (C-6), 156.4 (Arg-C), 163.9 
(CHO), 170.9 (Gly-CO), 172.0 (Asn-CO and Thr-CO), 173.1 
(Met-CO), 173.4 (Arg-CO), 174.0 (Ala-CO and Asn-C), 179.6 
(Ile-CO). HRMS for C41H68N17O16S2 ([M-H]-) calcd: 1116.4320 
found 1116.4305. 
6.1.12.3.  fMRTGNAI-SG (17c )  
1H NMR (600 MHz, D2O)  0.77 (t, 3H, J = 7.2 Hz, Ile--CH3), 
0.82 (d, 3H, J = 6.6 Hz, Ile--CH3), 1.05 (m, 1H, Ile--CH2, Ha), 
1.16 (d, J = 6.3 Hz, 3H, Thr--CH3), 1.24 (t, J = 3.6 Hz, TEA-
CH3), 1.32 (d, 3H, J = 7.2 Hz, Ala--CH3), 1.36 (m, 1H, Ile--CH2, 
Hb), 1.58 (m, 2H, Arg--CH2), 1.69-1.89 (m, 3H, Ile -CH and 
Arg--CH2), 1.94-2.08 (m+s, 5H, Met--CH2 and Met-SCH3), 
2.45-2.57 (m, 2H, Met--CH2), 2.70 (dd, 1H, J = 8.4 Hz and 15.6 
Hz, Asn--CH2, Ha), 2.80  (dd, 1H, J = 4.8 Hz and 16.2 Hz, Asn-
-CH2, Hb), 3.11 (t, 2H, J = 6.6 Hz, Arg--CH2), 3.16 (q, J = 7.8 
Hz, TEA-CH2), 3.89 (d, 1H, J = 6.6 Hz and 16.6 Hz, Gly--CH2, 
Ha), 3.95-4.02 (m, 2H, Ile--CH and Gly--CH2, Hb), 4.18-4.24 
(m, 1H, Thr--CH), 4.25-4.31 (m, 3H, H-5’a and H-5’b, Ala--
CH), 4.33-4.37 (m, 2H, J = 4.4 Hz, Thr--CH, H-4’), 4.37-4.43 
(m, 2H, Arg--CH, H-3’), 4.49 (dd, 1H, J = 5.9 Hz and 8.2 Hz, 
Met--CH), 4.66-4.72 (m, 2H, Asn--CH and H-2’), 5.89 (d, 1H, 
J = 6.6 Hz, H-1’), 8.00 (s, 1H, H-8), 8.08 (s, 1H, CHO). 13C NMR 
(150 MHz, D2O) -CH3Ile--CH3), 13.6 (Met-
SCH3), 14.5 (Ile--CH3Ala--CH3Thr--CH3 
23.8 (Ile--CH2), 23.9 (Arg--CH2), 27.7 (Arg--CH2), 28.7 (Met-
-CH2), 29.8 (Met--CH2), 35.8 (Asn--CH2), 36.5 (Ile--CH), 
40.1 (Arg--CH2), 42.1 (Gly--CH2), 46.0 (TEA-CH2), 49.5 (Ala-
-CH), 49.9 (Asn--CH), 51.1 (Met--CH), 53.0 (Arg--CH), 
58.6 (Thr--CH), 60.2 (Ile--CH), 66.9 (Thr--CH), 68.1 (C-5’), 
70.0 (C-3’), 73.1 (C-2’), 82.0 (C-4’), 85.9 (C-1’), 116.2 (C-5), 
136.3 (C-8), 151.4 (C-4), 156.0 (Arg-C), 163.7 (CHO), 170.6 
(Gly-CO), 171.5 (Asn-CO), 171.7 (Thr-CO), 173.1 (Met-CO), 
173.2 (Arg-CO), 173.7 (Ala-CO), 173.8 (Asn-C), 179.1 (Ile-CO). 
HRMS for C41H66N17O17S2 ([M-H]-) calcd: 1132.4269 found 
1132.4274. 
6.1.12.4.  fMRTGNAI-SI  (17d )  
1H NMR (600 MHz, D2O)  0.75 (t, 3H, J = 7.2 Hz, Ile--CH3), 
0.81 (d, 3H, J = 6.6 Hz, Ile--CH3), 1.04-1.10 (m, Ile--CH2, Ha, 
TEA-CH3), 1.16 (d, 3H, J = 6.3 Hz, Thr--CH3),1.29-1.37 (d+m, 
4H, J = 7.2 Hz, Ala--CH3 and Ile--CH2, Ha), 1.55 (m, 2H, Arg-
-CH2), 1.69-1.77 (m, 2H, Ile--CH and Arg--CH2, Ha), 1.79-
1.87 (m, 1H, Arg--CH2, Hb), 1.94-2.08 (m+s, 5H, Met--CH2 
and Met-SCH3), 2.45-2.57 (m, 2H, Met--CH2), 2.67-2.76 (m, 
TEA-CH2 and Asn--CH2, Ha), 2.80  (dd, 1H, J = 4.8 Hz and 16.2 
Hz, Asn--CH2, Hb), 3.10 (t, 2H, J = 6.6 Hz, Arg--CH2), 3.87 (d, 
1H, J = 16.8 Hz, Gly--CH2, Ha), 3.95-4.01 (m, 2H, Ile--CH and 
Gly--CH2, Hb), 4.18-4.24 (m, 1H, Thr--CH), 4.25-4.31 (m, 3H, 
H-5’a and H-5’b, Ala--CH), 4.33 (d, 1H, J = 4.4 Hz, Thr--CH), 
4.36-4.43 (m, 3H, Arg--CH, H-3’, H-4’), 4.48 (dd, 1H, J = 5.9 
Hz and 8.2 Hz, Met--CH), 4.67-4.73 (m, 2H, Asn--CH and H-
2’), 6.03 (d, 1H, J = 6.6 Hz, H-1’), 8.08 (s, 1H, CHO), 8.11 (s, 1H, 
H-2), 8.25 (s, 1H, H-8). 13C NMR (150 MHz, D2O) -
CH3Ile--CH3), 13.8 (Met-SCH3), 14.7 (Ile--
CH3Ala--CH3Thr--CH3 24.2 (Ile--CH2 and 
Arg--CH2), 27.5 (Arg--CH2), 28.8 (Met--CH2), 30.0 (Met--
CH2), 35.9 (Asn--CH2), 36.6 (Ile--CH), 40.0 (Arg--CH2), 42.2 
(Gly--CH2), 45.5 (TEA-CH2), 49.6 (Ala--CH), 50.0 (Asn--
CH), 51.3 (Met--CH), 53.2 (Arg--CH), 58.8 (Thr--CH), 60.4 
(Ile--CH), 66.9 (Thr--CH), 68.2 (C-5’), 70.3 (C-3’), 73.5 (C-
2’), 82.2 (C-4’), 86.1 (C-1’), 123.0 (C-5), 137.3 (C-8), 149.8 (C-
4), 153.6 (C-2), 156.2 (Arg-C), 164.0 (CHO), 167.3 (C-6), 170.9 
(Gly-CO), 171.8 (Asn-CO), 172.1 (Thr-CO), 173.3 (Met-CO), 
173.6 (Arg-CO), 174.0 (Ala-CO), 174.1 (Asn-C), 179.4 (Ile-CO). 
HRMS for C41H65N16O17S2 ([M-H]-) calcd: 1117.4160 found 
1117.4186. 
6.1.12.5.  fMRTGNAI-SC (17e )  
1H NMR (600 MHz, D2O)  0.82 (t, 3H, J = 7.2 Hz, Ile--CH3), 
0.88 (d, 3H, J = 6.6 Hz, Ile--CH3), 1.07-1.15 (m, 1H, Ile--CH2, 
Ha), 1.15-1.24 (m, Thr--CH3 and  TEA-CH3), 1.35 (d, 3H, J = 7.2 
Hz, Ala--CH3), 1.37-1.44 (m, 1H, Ile--CH2, Hb), 1.61 (m, 2H, 
Arg--CH2), 1.75 (m, 1H, Ile--CH), 1.84 (m, 2H, Arg--CH2), 
1.96-2.09 (m+s, 5H, Met--CH2 and Met-SCH3), 2.55 (m, 2H, 
Met--CH2), 2.70 (m, 1H, Asn--CH2, Ha) , 2.80  (dd, 1H, J = 4.8 
Hz and 16.2 Hz, Asn--CH2, Hb), 3.07 (m, TEA-CH2),  3.16 (t, 
2H, J = 6.6 Hz, Arg--CH2), 3.89 (d, 1H,  J = 5.4 Hz, Gly--CH2, 
Ha), 3.95-4.04 (m, 2H, Ile--CH and Gly--CH2, Hb), 4.18-4.25 
(m, 2H, H-2’ and Thr--CH), 4.27-4.33 (m, 4H, H-5’a, H-5’b, H-
3’ and Ala--CH), 4.34-4.45 (m, 3H, Thr--CH, Arg--CH and 
H-4’), 4.50 (dd, 1H, J = 5.9 Hz and 8.2 Hz, Met--CH), 4.68 (dd, 
1H, J = 5.2 Hz and 8.9 Hz, Asn--CH), 5.92 (d, 1H, J = 3.2 Hz, 
H-1’), 6.03 (d, 1H, J = 7.5 Hz, H-5), 7.82 (d, 1H, J = 7.5 Hz,  H-
6), 8.09 (s, 1H, CHO). 13C NMR (150 MHz, D2O) -
CH3Ile--CH3), 13.8 (Met-SCH3), 14.8 (Ile--
CH3Ala--CH3Thr--CH3 24.2 (Ile--CH2 and 
Arg--CH2), 27.5 (Arg--CH2), 28.8 (Met--CH2), 30.0 (Met--
CH2), 35.9 (Asn--CH2), 36.7 (Ile--CH), 40.1 (Arg--CH2), 42.2 
(Gly--CH2), 46.0 (TEA-CH2), 49.6 (Ala--CH), 50.0 (Asn--
CH), 51.3 (Met--CH), 53.2 (Arg--CH), 58.8 (Thr--CH), 60.4 
(Ile--CH), 66.9 (Thr--CH), 67.2 (C-5’), 69.0 (C-3’), 73.8 (C-
2’), 81.1 (C-4’), 89.1 (C-1’), 96.2 (C-5), 140.9 (C-6), 156.3 (Arg-
C), 157.4 (C-4), 164.0 (CHO), 165.8 (C-2), 170.9 (Gly-CO), 
171.9 (Asn-CO), 172.1 (Thr-CO), 173.4 (Met-CO), 173.6 (Arg-
CO), 174.1 (Ala-CO and Asn-C), 179.4 (Ile-CO). HRMS for 
C40H66N15O17S2 ([M-H]-) calcd: 1092.4208 found 1092.4196. 
6.1.12.6.  fMRTGNAI-SU (17f )  
 
 
 
 
 
 
 
 
1H NMR (600 MHz, D2O)  0.83 (t, 3H, J = 7.2 Hz, Ile--CH3), 
0.89 (d, 3H, J = 6.6 Hz, Ile--CH3), 1.07-1.16 (m, 1H, Ile--CH2, 
Ha), 1.18 (d, 3H, J = 8.4 Hz, Thr--CH3), 1.19-1.27  (t, J = 3.6 Hz, 
TEA-CH3), 1.36 (d, 3H, J = 7.2 Hz, Ala--CH3), 1.37-1.44 (m, 1H, 
Ile--CH2, Hb), 1.61 (m, 2H, Arg--CH2), 1.7-1.92 (m, 3H, Ile--
CH and 2H, Arg--CH2), 1.98-2.09 (m+s, 5H, Met--CH2 and 
Met-SCH3), 2.55 (m, 2H, Met--CH2), 2.70 (dd, 1H, J = 8.4 Hz 
and 15.6 Hz, Asn--CH2, Ha), 2.80 (dd, 1H, J = 4.8 Hz, and 16.2 
Hz, Asn--CH2, Hb), 3.17 (m, TEA-CH2 and Arg--CH2), 3.89 (d, 
1H, J = 16.9 Hz,  Gly--CH2, Ha), 3.98 (d, 1H, J = 16.9 Hz,  Gly-
-CH2, Hb), 4.01 (d, 1H, J = 6.9 Hz, Ile--CH), 4.19-4.37 (m, 8H, 
Thr--CH, Ala--CH, Thr--CH, Arg--CH, H-3’, H-4’, H-5’a-
and H-5’b), 4.41 (dd, 1H, J = 5.9 Hz and 8.2 Hz, Met--CH), 4.51 
(dd, 1H, J = 6.0 Hz, and 8.3 Hz, H-2’), 4.68 (dd, 1H, J = 5.2 Hz 
and 8.9 Hz, Asn--CH), 5.88 (d, 1H, J = 7.6 Hz,  H-5), 5.94 (d, 
1H, J = 5.3 Hz, H-1’), 7.79 (d, 1H, J = 7.6 Hz, H-6), 8.09 (s, 1H, 
CHO). 13C NMR (150 MHz, D2O) -CH3Ile--
CH3), 13.8 (Met-SCH3), 14.8 (Ile--CH3Ala--
CH3Thr--CH3 24.2 (Ile--CH2), 24.3 (Arg--CH2), 27.6 
(Arg--CH2), 28.8 (Met--CH2), 30.0 (Met--CH2), 35.9 (Asn--
CH2), 36.6 (Ile--CH), 40.1 (Arg--CH2), 42.2 (Gly--CH2), 46.3 
(TEA-CH2), 49.5 (Ala--CH), 50.0 (Asn--CH), 51.3 (Met--
CH), 53.2 (Arg--CH), 58.8 (Thr--CH), 60.4 (Ile--CH), 66.8 
(Thr--CH), 67.6 (C-5’), 69.4 (C-3’), 73.4 (C-2’), 81.5 (C-4’), 
88.2 (C-1’), 102.4 (C-5), 140.8 (C-6), 156.3 (Arg-C), 152.8 (C-
2), 164.0 (CHO), 167.4 (C-4), 170.9 (Gly-CO), 171.9 (Asn-CO), 
172.1 (Thr-CO), 173.3 (Met-CO), 173.6 (Arg-CO), 174.0 (Ala-CO 
and Asn-C), 179.5 (Ile-CO). HRMS for C40H65N14O18S2 ([M-H]-) 
calcd: 1093.4048 found 1093.4047. 
6.1.12.7.  fMRTGNAI-S(4-ABI)  (17g )  
1H NMR (600 MHz, D2O)  0.76 (t, 3H, J = 7.2 Hz, Ile--CH3), 
0.84 (d, 3H, J = 6.6 Hz, Ile--CH3), 1.05-1.11 (m, 1H, Ile--CH2, 
Ha), 1.16 (d, 4H, J = 6.3 Hz, 3H, Thr--CH3), 1.22 (t, J = 3.6 Hz, 
TEA-CH3), 1.30 (d, 3H, J = 7.2 Hz, Ala--CH3), 1.36-1.40 (m, 1H, 
Ile--CH2, Hb), 1.51-1.60 (m, 2H, Arg--CH2), 1.60-1.72 (m, 1H, 
Ile--CH), 1.77-1.85 (m, 2H, Arg--CH2), 1.94-2.08 (m+s, 5H, 
Met--CH2 and Met-SCH3), 2.47-2.58 (m, 2H, Met--CH2), 2.97  
(dd, 1H, J = 8.4 Hz and 15.6 Hz, Asn--CH2, Ha), 2.78 (dd, 1H, J 
= 4.8 Hz, and 16.2 Hz, Asn--CH2, Hb), 3.05-3.15 (m, Arg--CH2 
and TEA-CH2), 3.87 (dd, 1H, J = 6.6 Hz and 16.6 Hz, Gly--CH2, 
Ha), 3.94-4.03 (m, 2H, Ile--CH and Gly--CH2, Hb), 4.17-4.23 
(m, 1H, Thr--CH), 4.23-4.29 (m, 1H, Ala--CH), 4.30-4.43 (m, 
6H, Thr--CH, Arg--CH, H-3’, H-4’, H-5’a and H-5’b), 4.48 (t, 
1H, J = 7.2 Hz, Met--CH), 4.64-4.68 (m, 2H, Asn--CH and H-
2’), 5.99 (d, 1H, J = 6.0 Hz, H-1’), 6.73 (d, 1H, J = 7.2 Hz,  H-5), 
7.15-7.21 (d+tr, 2H, H-6, and H-7), 8.01 (s, 1H, CHO), 8.31 (s, 
1H, H-2). 13C NMR (150 MHz, D2O) -CH3Ile-
-CH3), 13.8 (Met-SCH3), 14.8 (Ile--CH3Ala--
CH3Thr--CH3 24.2 (Ile--CH2 and Arg--CH2), 27.5 
(Arg--CH2), 28.8 (Met--CH2), 30.0 (Met--CH2), 35.9 (Asn--
CH2), 36.6 (Ile--CH), 40.0 (Arg--CH2), 42.2 (Gly--CH2), 46.2 
(TEA-CH2), 49.6 (Ala--CH), 49.9 (Asn--CH), 51.3 (Met--
CH), 53.2 (Arg--CH), 58.7 (Thr--CH), 60.4 (Ile--CH), 66.9 
(Thr--CH), 68.1 (C-5’), 70.0 (C-3’), 72.6 (C-2’), 82.3 (C-4’), 
88.2 (C-1’), 102.1 (C-7), 108.5 (C-5), 124.8 (C-6), 132.2 (C-9), 
133.0 (C-8) 137.4 (C-4), 140.7 (C-2), 156.2 (Arg-C), 164.0 
(CHO), 170.9 (Gly-CO), 171.8 (Asn-CO), 172.1 (Thr-CO), 173.3 
(Met-CO), 173.6 (Arg-CO), 174.0 (Ala-CO), 174.1 (Asn-C), 
179.4 (Ile-CO). HRMS for C43H68N15O16S2 ([M-H]-) calcd: 
1114.4415 found 1114.4412. 
6.2. Model building and analysis 
With the E coli Ile-tRNA synthetase structure being not 
available in the protein databank, a homology model was created 
using the I-tasser server.36 The sequence of the enzyme was taken 
from the uniprot database (enzyme code EC=6.1.1.5 and uniprot 
id P00956). As single 3D template structure, we used the E coli 
methionyl-tRNA synthetase structure (1PG0) belonging to the 
same class I of tRNA synthetases. This structure contains a 
methionyl adenylate analogue inhibitor similar to the seven 
inhibitors used in this study, and therefore was used as template 
for our adenylate inhibitor. Additionally, the threonyl sulfamoyl 
adenosine inhibitor found in structure 3UH047 was used to 
complete part of the sulfamoyl tail in our inhibitor structures. The 
six inhibitors having different bases were built by superimposing 
the respective base onto the adenosine using quatfit. The 
homology model of E coli Ile-tRNA synthetase was then 
superimposed onto structure 1PG0 using dali.48  
All seven inhibitors were then superimposed onto the original 
inhibitor present in 1PG0 resulting in seven complexes of E coli 
Ile-tRNA synthetase with inhibitor. As no interactions were seen 
between the base atoms of the pyridine inhibitors and the enzyme 
pocket, the uridine and cytosine inhibitors were repositioned with 
the base coinciding with the six-membered ring of the adenine 
base. The complexes were prepared for use in the AMBER 
software.49 The parameters for enzyme structure were taken from 
the ff99bsc0 force field.50 The seven ligand molecules were 
parameterized with Antechamber using the gaff force field.51 
Some patches were introduced to the parameters to get the right 
conformation for the base atoms and the sulfamoyl group after 
energy minimization. The molecular mechanics energy of the 
complexes was minimized using 500 steps. Then the mm/pbsa 
method52 was applied on the minimized complexes to obtain the 
binding energies for the different inhibitors. Visual inspection53 
together with a ligplot analysis54 was used for interpretation. 
6.3. Biological activity experiments 
6 .3 .1 .  Whole ce l l  ac t iv i ty  de terminat ions  
The respective bacteria were grown overnight in Luria Broth 
(LB) medium and cultured again the following day in fresh LB 
medium or LB-medium containing 5 mM (L)-arabinose. 
Compounds were titrated in a 96-well plate using either LB-
medium +/- 5 mM (L)-arabinose to dilute the compounds. To each 
well, 85 µL LB-medium +/- 5 mM (L)-arabinose was added to a 
total volume of 90 µL. Next, 10 µL of bacterial cell culture grown 
to a OD600 of 0.1 was added. The cultures were next placed into a 
Tecan Infinite M200® incubator and shaken at 37 °C. The OD600 
was determined after 8 h and 18 h, respectively. The broth dilution 
tests were performed in duplicate. 
 
 
 
 
 
 
 
 
Bacterial strains used for the evaluations: E. coli Ara-Yej 
(BW39758), expressing the YejABEF transporter upon L-
arabinose induction; E. coli wt used as wild type control. The 
antibacterial activities of all compounds were determined by 
monitoring the optical density of suspensions of cell-cultures. 
6.3.2 .  Aminoacyla t ion  exper iments  
To assess the degree of inhibition of the aminoacylation 
reaction, in vitro tests were performed using the relevant S30 cell 
extracts. 
Preparation of S30 cell extracts. Cells were grown in 50 mL 
LB-medium. After centrifugation at 3000 g for 10 min the 
supernatant was discarded and the pellet was resuspended in 40 
mL buffer containing: Tris.HCl or Hepes.KOH (pH = 8.0; 20 
mM), MgCl2 (10 mM), KCl (100 mM). The cell suspension was 
centrifuged again at 3000 g. This procedure was repeated twice. 
The pellet was resuspended in 1 mL of the following buffer 
Tris.HCl or Hepes.KOH (pH = 8.0; 20 mM), MgCl2 (10 mM), KCl 
(100 mM), DTT (1 mM) and kept at 0 °C. Subsequently, the cells 
were sonicated for 10 s and left at 0 °C for 10 min. This procedure 
was repeated 5-8 times. The lysate was centrifuged at 15000 g for 
30 min at +4 °C.  
tRNA aminoacylation reaction: To 1 μL of solution containing 
inhibitor, 3 μL of E. coli S30 extracts was added. Next, 16 μL of 
the following aminoacylation mixture was added: Tris.HCl (30 
mM, pH 8.0), DTT (1 mM), bulk of E. coli tRNA (5 g/l), ATP (3 
mM), KCl (30 mM), MgCl2 (8 mM), and the specified, 14C-
radiolabeled amino acid (40 μM, 200 Ci/mmol). The reaction 
products were precipitated in cold 10% TCA on Whatman 3MM 
papers, 5 min. after the aminoacylation mixture was added. The 
aminoacylation reaction was carried out at room temperature. 
Depending on whether or not processing was needed, variable time 
intervals were included between the addition of the cell extract and 
the addition of the aminoacylation mixture. After thorough 
washing with cold 10% TCA, the papers were washed twice with 
acetone and dried on a heating plate. Following the addition of 
scintillation liquid (12 mL), the amount of radioactivity was 
determined in a Tri-card 2300 TR liquid scintillation counter. 14C-
Radiolabeled amino acids and scintillation liquid were purchased 
from Perkin Elmer. 
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FIGURE LEGENDS: 
 
Figure 1: Isoleucyl-sulfamoyl adenosine (1a), its deoxygenated variants (1b-d) and the aryl-
tetrazole containing analogues (2-3) from Cubist Pharmaceuticals as IleRS 
inhibitors. 
 
Figure 2: Albomycin congeners (4a-c) and microcin C (5a) as examples of Trojan-Horse 
antibiotics 
 
Figure 3: In vitro aminoacylation reaction in presence of the respective aaSA analogues 
16a-16g using S30 cell extract of E. coli wt.  
 
Figure 4: Homology model for E. coli IleRS based on the 1PG0 structure (see methods) 
including its interactions with the sulfamoylated adenosine analogue 16b. 
 
Figure 5: Broth dilution antibacterial activity test against E. coli wt in LB medium at 
different concentrations of the hexapeptidyl conjugates 17a-17g.  
 
Figure 6: Broth dilution antibacterial test against E. coli Ara-Yej (BW39758) strain in LB 
medium containing 5 mM L-arabinose at different concentrations of the 
hexapeptidyl conjugates 17a-17g as determined after incubation for 8 h (panel A) 
and after 18 h (panel B). 
 
 
SCHEME LEGENDS: 
 
Scheme 1: Synthesis of 1-(-D-ribofuranosyl)-4-nitrobenzimidazole 
 Reagents and conditions: (i) ethanol, selenium dioxide, reflux 10 min, 99%; (ii) 
conc. H2SO4 and conc. HNO3 from 0o to rt in 30 min, 100%; (iii) conc. HCl, aq. HI 
(57%), 3 h, 54%; (iv) triethyl orthoformate, reflux, 4 h then formic acid relux 3 h, 
87%; (v) tetra-O-acetyl ribofuranose, SnCl4 (1M solution in DCM), dry ACN, 25 
oC, 16 h, 80%; (vi) 7N ammonia in methanol, rt, overnight, 90%. 
 
Scheme 2: Synthetic scheme for assembly of 5'-O-(N-isoleucyl)-sulfamoyl adenosine and its 
different base analogues (16a-g). 
 Reagents and conditions: (i) TBDMSCl, imidazole, dry DMF, 50 oC, 3 d, 92-
98%; (ii) TFA-Water, THF, 0 oC, 6 h, 90-99%; (iii) ClSO2NCO, formic acid, DMA, 
63-80%; (iv) Boc-Ile-OSu, DBU, DMF, rt, 6 h, (v) TFA:water (5:2), rt, 3 h, (vi) 
TEA.3HF, THF, rt, overnight 28-65% (over 3 steps); (vii) Pd/C, methanol: water, 
H2 atm, rt, 6 h, 40%. 
 
Scheme 3: Strategy for synthesis of the different nucleoside sulfamate-hexapeptidyl 
conjugates (17a-g). 
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 Reagents and conditions: (i) DIC, HOBt, DIPEA, DMF, 16 h, (ii) 
TFA/water/thioanisole (90:7.5:2.5), rt, 2 h, 6-12 % (over 2 steps, after HPLC 
purification) 
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